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ABSTRACT 
 
 The control of extracellular adenosine is crucial to the regulation of synaptic transmission 
and neuroprotection.  Equilibrative nucleoside transporters (ENTs) are highly expressed in the 
hippocampus and widely accepted as critical regulators of adenosine tone.  However, the 
mechanisms regulating the surface distribution and transport function of ENTs are largely 
unknown.  Since ENT1 and ENT2 contain consensus sequences for phosphorylation by protein 
kinase CK2, and because this protein has been reported to regulate synaptic plasticity and ENT 
function in non-neuronal systems, the present thesis outlines the hypothesis that CK2-induced 
phosphorylation of ENTs is important for their cellular localization and thus the regulation of 
adenosine tone and synaptic transmission.  Here, a functional interaction between adenosine 
CK2, ENTs and AMPA receptors in the hippocampus is reported.  Western blot analysis shows 
that a variety of CK2 inhibitors (DMAT, TBB and DRB) significantly reduced the density of 
ENT1 and ENT2 proteins in hippocampal membrane fractions, suggesting that CK2-mediated 
phosphorylation of ENTs promotes their surface localization.  In contrast, it was found that the 
ENT1 inhibitor NBTI significantly increased in the membrane localization of ENT1, relative to 
the control.  Moreover, ENTs were found to immunoprecipitate with GluR1 and GluR2-
containing AMPA receptors; and CK2 inhibitors caused a decrease in the membrane localization 
of GluR2 and GluR1 AMPA receptors.   These results suggest a novel signaling complex linking 
CK2-regulated adenosine transport to AMPA receptor trafficking in the rat hippocampus.  
Although the physiological significance of these findings requires further investigation, this 
thesis provides insight into an adenosine regulation pathway that may be important for the 
regulation of synaptic transmission and neuroprotection in the rat hippocampus.   
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CHAPTER 1 
 
INTRODUCTION 
 
 
1.1 Adenosine 
 
Adenosine serves many important roles in the central nervous system, and it is evident 
that one of its major roles is as a dynamic modulator of neurotransmission.  Due to the inherent 
neuroprotective properties of adenosine, there is an increasing amount of interest in the study of 
adenosine and its implications in the protection against neuronal damage that occurs during 
stroke and ischemic attack; however, the regulatory mechanisms for controlling the extracellular 
adenosine that activates its receptors requires further investigation.   
 
1.1.1 Adenosinergic signaling in the nervous system 
 
 Adenosine is a well-known purine nucleoside that has many physiological implications in 
the central nervous system.  Adenosine, as a nucleoside, plays a crucial role as a metabolic 
precursor in nucleic acid synthesis; in addition to its function in the control of sleep, and the 
coupling of cerebral blood flow to energy demand (Phillis, 1989; Brundege and Dunwiddie, 
1997), adenosine has an important role as a neuroprotective agent against ischemic and seizure 
induced neuronal cell damage (Dunwiddie and Masino, 2001). 
 Adenosine acts via four subtypes of membrane receptors: A1, A2a, A2b and A3, which are 
coupled to G proteins.  The A1 and A3 receptors are coupled to Gi proteins and cause inhibition 
of adenylyl cyclase, whereas the A2a and A2b receptors couple to Gs proteins that induce the 
stimulation of adenylyl cyclase and cause a subsequent increase in cyclic-AMP (cAMP) levels 
(Fredholm et al., 2005).  Among the four types of adenosine receptors, A1 and A2a have the 
highest affinity for adenosine (~70 and 150nM, respectively), and basal extracellular levels of 
adenosine (~25-250nM) are enough to tonically activate a considerable proportion of these 
receptors (Dunwiddie and Masino, 2001; Blank et al., 2007), implying that some effects of 
adenosine are already exerted under basal conditions.   
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 The A1 receptor, which has the highest abundance in the brain, has an overall inhibitory 
effect on neurotransmission (Dunwiddie, 1985).  The inhibitory action of A1 receptors results 
from combined post-synaptic hyperpolarization, due to the activation of potassium channels, and 
the pre-synaptic inhibition of neurotransmitter release, predominantly thought to be due to 
inhibition of N-type calcium channels (Sebastiao et al., 2000; Cunha, 2001).  In contrast, the A2a 
receptor, which is abundant in only a few areas of the brain, is primarily stimulatory, promoting 
the release of neurotransmitters pre-synaptically (Dunwiddie and Masino, 2001).  Under the 
regulation of adenosine is the release of a wide variety of neurotransmitters, including glutamate, 
gamma-aminobutyric acid (GABA), acetylcholine and dopamine (Blank et al., 2007).  While 
adenosine exerts some regulatory effect on inhibitory systems, its main effect is the suppression 
of excitatory glutamatergic signaling (Dunwiddie, 1985). 
 
1.1.2 Adenosine formation 
  
 There are two well-known pathways for adenosine formation. As illustrated in Figure 1.1, 
adenosine can be formed either extra- or intracellularly in the CNS.  Extracellularly, adenosine is 
produced by the metabolism of released nucleotides, by the enzyme ecto-5’-nucleotidase, which 
can be inhibited by ATP, ADP, and , -methylene adenosine diphosphate (Latini and Pedata, 
2001).  In addition to the formation of adenosine from nucleotides, extracellular adenosine may 
also be produced from the metabolism of cAMP (Latini and Pedata, 2001). 
 Intracellularly, adenosine is formed from the dephosphorylation of AMP by cytosolic 5’-
nucleotidase; adenosine then exits the cell via bi-directional nucleoside transporters.  Adenosine 
can also be formed intracellularly from S-adenosylhomocysteine (SAH) by SAH hydrolase, 
however this pathway appears to be a less significant source (Parkinson et al., 2005).  These 
intracellular enzymes respond to only large increases in AMP during increased metabolic 
activity, and for this reason the intracellular formation of adenosine from catabolism of cytosolic 
ATP has been proposed to represent a very sensitive signal of increased metabolic rate or 
metabolic stress (Latini and Pedata, 2001).   
 Therefore, under hypoxic or ischemic conditions when intracellular ATP is depleted, 
intracellular formation of adenosine predominates.  In contrast, under normoxic conditions, 
extracellular adenosine is derived mainly from released nucleotides (Latini and Pedata, 2001; 
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Parkinson et al., 2005).  Recently, it has been suggested that astrocytes and neurons respond 
differently in terms of their adenosine formation when exposed to ischemic-like conditions 
(Parkinson et al., 2005).  Under such conditions, neurons respond by producing adenosine 
intracellularly whereas astrocytes release adenine nucleotides that are then metabolized to 
adenosine (Parkinson et al., 2005).  
 
1.1.3 Adenosine metabolism 
  
 The inactivation of extracellular adenosine is accomplished by the uptake across the cell 
membrane of neurons and neighboring cells, followed by either the phosphorylation of adenosine 
back to AMP by adenosine kinase or its deamination to inosine by adenosine deaminase (Latini 
and Pedata, 2001).  These processes are summarized in Figure 1.1.  Under normal physiological 
conditions, it is proposed that the predominant pathway of adenosine metabolism is 
phosphorylation by adenosine kinase, and that deamination becomes more important only at 
higher adenosine concentrations, such as under ischemic conditions.  Adenosine kinase inhibitors 
appear to be much more effective at increasing the concentration of extracellular adenosine than 
adenosine deaminase inhibitors (Sciotti and Van Wylen, 1993; Pazzagli et al., 1995).  It has also 
been shown that adenosine kinase activity is inhibited during hypoxic conditions and during the 
elevation of adenosine concentration (Pak et al., 1994), and that this can significantly effect 
synaptic transmission.  This suggests an amplification mechanism for intracellular adenosine 
formation during metabolically stressful events, which illustrates the importance of adenosine’s 
neuroprotective role in the CNS (Parkinson et al., 2005), as discussed subsequently.     
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Figure 1.1. Pathways of adenosine formation and metabolism.  Abbreviations are as follows: ADA, adenosine 
deaminase; AK, adenosine kinase; cAMP, cyclic AMP; PDE, cAMP phosphodiesterase; SAH, S-adenosyl 
homocysteine.  Released cAMP (via non-specific, energy-dependent  cAMP transporter) contributes to extracellular 
source of adenosine.  Adapted from Latini et al., 2001. 
 
 
1.1.4 Neuroprotective role of adenosine 
 
One of adenosine’s main roles in the central nervous system is as a modulator of 
neurotransmission.  It is well known that during hypoxia, hypoglycemia or ischemia, there is an 
imbalance between the rates of energy demand and energy delivery; as a result, the levels of 
extracellular adenosine increase considerably (Cunha, 2001; Fredholm et al., 2005).  This 
elevation in extracellular adenosine can be attributed to the release of adenosine by ischemic 
brain cells and from metabolized ATP derived from astrocytes (Cunha, 2001; Benarroch, 2008). 
 It is widely known that extracellular adenosine acts as a neuromodulator, in part, by 
inhibiting excitatory synaptic transmission through the activation of adenosine A1 receptors, and 
may also act as an endogenous neuroprotectant by reducing glutamate excitotoxicity (Dunwiddie 
and Masino, 2001).  In models of ischemia, it has been shown that both adenosine and A1 
agonists, when acutely administered, are neuroprotective.  Moreover, the administration of A1 
receptor antagonists can increase neuronal death in models of ischemia (Cunha, 2001; Olsson et 
al., 2004; Fredholm et al., 2005).  However, the deletion of the A1 receptor gene in knockout 
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mice does not change the density of ischemic brain injury, suggesting that there are 
compensatory neuroprotecitve mechanisms in place that do not rely on adenosine A1 receptor 
signaling (Olsson et al., 2004).  However, further elucidation of these neuroprotective systems in 
these transgenic animals is warranted.   
 The adenosine A2a receptor has also been shown to have implications in neuroprotection 
(Ongini et al., 1997; Chen et al., 1999).  However, unlike the A1 receptor, activation of the A2a 
receptors may contribute to neuronal damage, as a massive release of excitatory amino acids 
during ischemia is believed to be important in subsequent neuronal death (Latini and Pedata, 
2001; Nishizaki, 2004; Fredholm et al., 2005).  Furthermore, A2a agonists have been shown to 
enhance glutamate release under ischemic as well as non-ischemic conditions, thus A2a 
antagonism may potentially offer neuroprotection, which has been confirmed in a global 
ischemia model as well as other ischemic and excitotoxicity models (Fredholm et al., 2005).  
Conversely, A2a receptor agonists have also been shown to elicit neuroprotective effects, 
however these effects are most likely mediated via the activation of non-neuronal A2a receptors 
and the initiation of processes such as vasodilation and the inhibition of inflammation by 
attenuating the release of pro-inflammatory cytokines (Cunha, 2001; Fredholm et al., 2005). 
To date, there is little information about the role of A2b receptors in neuroprotection, and 
the literature describing A3 adenosine receptor stimulation under ischemic conditions are 
conflicting, some reporting beneficial and others reporting deleterious effects (von Lubitz, 1999). 
 
1.1.5 A1 and A2a receptor signaling 
 
Adenosine acts as a modulator at the synapse, controlling neurotransmitter release and the 
responsiveness of the post-synaptic cells.  Adenosine accomplishes this by activating inhibitory 
A1 receptors or facilitatory A2a receptors; yet, adenosine’s overall neuromodulatory effects are 
thought to result from a balanced activation of A1 and A2a receptors (Lopes et al., 1999a). 
 The densities of these adenosine receptors vary between different regions of the brain.  
A1 receptors are found mostly in neurons but are also expressed in other cells such as microglia 
and astrocytes, and are concentrated at the nerve terminals in the hippocampus, cerebral cortex 
and cerebellum (Fredholm et al., 2005).  A2a mRNA is highly enriched in the striatum and in 
lower amounts in the lateral septum, cerebellum, cortex, and hippocampus (Fredholm et al., 
 6 
2005).  However, the densities of these receptors are not static and are known to change with age 
(Cunha et al., 1995; Ekonomou et al., 2000).  In the hippocampus, it was found that the density 
of A1 receptor binding in aged rats was reduced compared to young adult rats, while density of 
A2a receptor binding was found to increase in the hippocampus with age (Cunha et al., 1995).  
These changes in adenosine receptor subtypes are thought to be due to a change in expression of 
the receptor within the cell rather than general neuronal degeneration (Ekonomou et al., 2000). 
 There is increasing evidence that adenosine A1 and A2a receptors not only have opposite 
effects, but also interact with each other (Dixon et al., 1997; Lopes et al., 1999b; Rebola et al., 
2003).  This interaction has been shown to change with age.  The A2a receptor-mediated 
facilitation of hippocampal synaptic transmission has been shown to be larger in aged than in 
young adult rats, and it is thought to be due to not only increased A2a receptor density in nerve 
terminals,
 
but also a modified transducing system operated by A2a receptors (Rebola et al., 
2003). 
 In synaptosomes of the striatum, and in hippocampal and cortical nerve terminals of 
young adult rats, it has been shown that the activation of A2a receptors causes a desensitization 
of A1 receptors by decreasing the binding of A1 receptor agonists, which required the activation 
of PKC (Dixon et al., 1997; Lopes et al., 1999b).  However, in aged rats, the activation of A2a 
receptors no longer caused desensitization of A1 receptors, and the role of A2a receptors had 
changed from mostly a modulator of A1 responses in young adult rats to a direct PKA-dependent 
facilitation of glutamate release in aged rats (Lopes et al., 1999b; Rebola et al., 2003).  It is also 
of note that in aged rats when compared to younger rats, an adenosine A1 receptor agonist, 
administered at a supramaximal concentration, was less efficient in inhibiting whereas, A2a 
receptor activation was more efficient at facilitating acetylcholine release, further indicating an 
enhanced role of A2a-specific adenosine signaling in aged rats (Cunha, 2001).  It is therefore 
possible that, with these changes in the balance between A1 and A2a adenosine signaling, 
increased extracellular adenosine may lead to greater A2a receptor activation and enhanced 
neurotoxicity during metabolically stressful insults to the brain.  
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1.2 Nucleoside transporters 
 
Adenosine, like other nucleosides, is a hydrophilic molecule and therefore relies on 
particular transport proteins for efficient movement across cellular membranes.  Two major 
families of nucleoside transporters have been identified in mammalian cells, concentrative 
nucleoside transporters (CNTs) and equilibrative nucleoside transporters (ENTs) (Baldwin et al., 
2004; Kong et al., 2004).  Within these families exist multiple subtypes which can be separated 
from one another based on their substrate specificity, inhibitor sensitivities, molecular 
characteristics and tissue distribution, although there is some overlap between the transporter 
subtypes (Kong et al., 2004).   
Concentrative nucleoside transporters are cation symporters that mediate the 
unidirectional transport of nucleosides against their concentration gradient, in contrast to 
equilibrative nucleoside transporters, which are Na
+
-independent and mediate the bidirectional 
flux of nucleosides across the plasma membrane in accordance with their concentration gradient.  
Although there are concentrative nucleoside transporters expressed in some regions of the central 
nervous system (Li et al., 2001; Redzic et al., 2005), the ENT subtype of nucleoside transporters 
appears to dominate.  ENT1 and ENT2 are the two best-characterized equilibrative nucleoside 
transporters, and have ubiquitous tissue distribution compared to the other ENT subtypes.  In 
addition, these ENT isoforms are highly expressed in pyramidal neurons of the hippocampus, an 
area of the brain that is highly susceptible to ischemic neuronal damage (Anderson et al., 1999a; 
Anderson et al., 1999b).  Much less is known about ENT3 and ENT4, and to date they seem to 
only have a minor role in purinergic signaling events (Baldwin et al., 2004; Barnes et al., 2006; 
Parkinson et al., 2009). 
 
1.2.1 Equilibrative nucleoside transporters: characteristics and topology 
 
Prior to the identification of their genes in the late 1990’s, members of the equilibrative 
nucleoside transport family were categorized based on their sensitivity to the inhibitor 
nitrobenzlthioinosine (nitrobenzylmercaptopurine ribose; NBMPR) (Kiss et al., 2000; Kong et 
al., 2004). There were two subtypes in this family, designated es and ei, corresponding to 
equilibrative sensitive and equilibrative insensitive, respectively (Kiss et al., 2000; Kong et al., 
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2004; Podgorska et al., 2005).  The es subtype binds NBMPR with high affinity and is inhibited 
at nanomolar concentrations (Kd 1-10nM), whereas the ei subtype is only slightly inhibited by 
NBMPR at high concentrations (>10 M) (Kong et al., 2004).  The es and ei transporters have 
since been cloned and renamed ENT1 and ENT2, respectively (Griffiths et al., 1997b; Griffiths et 
al., 1997a; Crawford et al., 1998).  In addition to ENT1 and ENT2, the cDNAs of two other 
mammalian ENT members (ENT3 and ENT4) have been isolated and identified (Hyde et al., 
2001).  All four members of the ENT family are capable of transporting adenosine, however they 
vary in their affinity for this nucleoside (Young et al., 2008).  Where ENTs differ most in their 
substrate specificity is their ability to transport other nucleosides and nucleobases.  ENT1 and 
ENT2 have similar broad substrate specificity for purine and pyrimidine nucleosides, however 
ENT2 possess the ability to transport nucleobases (guanine, thymine, and uracil) (Baldwin et al., 
2004).  The different affinities to various nucleosides and nucleobases of these ENTs are 
summarized in Table 1.1.  
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Table 1.1 Properties of mammalian nucleoside transporters 
 
Note: h, Human; r, rat; m, mouse; rb, rabbit.  Reproduced with permission from Young et al., 2008. 
 
  
 Human ENT1 and ENT2, localized to chromosome 6p21 and 11q13 (respectively), each 
contain 465 residues, are ~50% identical in their sequence, and share an 11 transmembrane 
domain topology with an intracellular N-terminus and an extracellular C-terminus (see Figure 
1.2) (Baldwin et al., 1999; Kong et al., 2004).  The 457-residue rat homologue of ENT1 is 78% 
identical in sequence to the human ENT1 protein, and the 460-residue mouse homologue is 79% 
identical (Griffiths et al., 1997b; Yao et al., 1997; Handa et al., 2001; Young et al., 2008).  
Human ENT1 is glycosylated at Asn48, on the N-terminus in the large extracellular loop between 
transmembrane domains one and two (Griffith and Jarvis, 1996).  This glycosylation of hENT1 
may, in part, affect the binding affinity to inhibitors such as NBMPR, but is not required for its 
transport activity.  Two glycosylation sites (Asn47 and Asn56) are present in the large 
extracellular loop of hENT2; while glycosylation has not been shown to be essential for ENT 
transport activity, it is required for efficient targeting of the protein to the plasma membrane 
(Ward et al., 2003; Kong et al., 2004).  hENT2 also possesses a C-terminal dileucine repeat that 
is associated with the surface expression of hENT2 (Kong et al., 2004).  It was recently 
discovered, by Coe et al. 2009, that mutations within a highly conserved PWN (proline, 
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tryptophan, asparagine) motif near the N-terminus of hENT1 disrupt plasma membrane 
localization in transfected MCF-7 and COS-7 cells (MCF-7, breast cancer cell line; COS-7, 
monkey kidney fibroblast cell line).  This group also found that C-terminal mutations led to 
hENT1 retention within the cell (Nivillac et al., 2009). 
 The third subtype in the ENT family, ENT3, exhibits ~30-33% sequence identity to ENT1 
and ENT2 (Hyde et al., 2001).  The presence of two dileucine motifs, distinctive of endosomal, 
lysosomal targeting motifs, in the long hydrophilic N-terminal region of this transporter suggests 
that it may be an intracellular transporter (Baldwin et al., 2004; Kong et al., 2004; Podgorska et 
al., 2005). 
 The fourth transporter belonging to the ENT family, ENT4, also transports nucleosides and 
exhibits a novel pH-dependent adenosine transport activity that is optimal at acidic pH (Barnes et 
al., 2006).  This transporter has an affinity for adenosine that is intermediate between ENT2 and 
ENT3.  The 528-residue mouse homologue is 86% identical in sequence to the 530-residue 
human ENT4 protein (Barnes et al., 2006).  It is suggested that this transporter has ubiquitous 
tissue distribution, and that it participates in adenosine transport under acidic conditions, such as 
those associated with ischemia (Barnes et al., 2006).  Human and mouse ENT3 and ENT4 have 
glycosylation sites in the TM1–2 loop and C-terminal tail, respectively, but glycosylation status 
of these transporters remains unknown (Baldwin et al., 2004).   
 
 
Figure 1.2. Topology of hENT1 (A) and hCNT1 (human Concentrative Nucleoside Transporter-1) (B). Grey 
rectangles indicate transmembrane α-helices. Black circles indicate glycosylation sites in hENT1 (Vickers et al., 
1999) and hCNT1 (Loewen et al., 1999). Reproduced with permission from Podgorska et al. 2005. 
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1.2.2 Localization of equilibrative nucleoside transporters in the CNS 
 
Equilibrative nucleoside transporters, in particular ENT1, but also ENT2 are considered 
to be ubiquitous throughout the body, although there is considerable variability in the abundance 
of these transporters among tissue types.  ENT1 is expressed in a variety of cells, including 
erythrocytes and placenta, brain, liver, lung, and heart tissue (Kong et al., 2004).  Likewise, 
ENT2 is expressed in a variety of tissues, such as vascular endothelium, heart, brain, placenta, 
thymus, pancreas, intestine, prostate and kidney, with a predominant expression in skeletal 
muscle tissue (Griffiths et al., 1997a). 
 In the central nervous system, the distribution of human ENT1 mRNA is widespread, with 
the highest levels observed in the caudate nucleus and amygdala, followed by intermediate levels 
in the hippocampus, subthalamic nucleus, thalamus and corpus callosum, with lower levels 
detected in the substantia nigra (Anderson et al., 1999b).  The work of Jennings et al. in 2001 
showed that the expression of hENT1 protein throughout the human brain correlated well with 
the distribution of hENT1 mRNA reported by Anderson et al. 1999.  Human ENT1 protein was 
most abundant in the cerebral cortex, while moderate levels were seen in the thalamus, midbrain 
and basal ganglia, with the lowest amounts of hENT1 seen in the hippocampus, medulla, pons 
and cerebellum (Jennings et al., 2001). 
  RT-PCR and in situ hybridization and Northern blot revealed a wide regional distribution 
of rENT1 and rENT2 mRNA in rat brain, and suggested that the regional distribution of ENT1 
and ENT2 is somewhat different in rat brain than in the human brain (Anderson et al., 1999a; 
Anderson et al., 1999b).  Rat ENT1 mRNA was found in several neuron populations in the 
hippocampus, cortex, striatum, and cerebellum, with strong hybridization signals in pyramidal 
neurons of the hippocampus, granule cells of the dentate gyrus, and in cerebellar granule and 
Purkinje neurons (Anderson et al., 1999b).  Rat ENT1 mRNA also appeared in astrocytes, 
vascular smooth muscle cells, and choroid epithelial cells (Anderson et al., 1999b).  In another 
study by the same group, it was found that rENT2 mRNA is present in several brain regions, 
including the superior colliculus, hippocampus, cerebral cortex, striatum and cerebellum, and a 
variety of tissues including neurons, astrocytes, vascular smooth muscle cells and epithelial cells 
of the choroid plexus (Anderson et al., 1999a).  However, using [
3
H]-NBMPR autoradiography 
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as a method to localize ENT1 transporter proteins in the rat brain, Anderson et al. found several 
differences between the distribution of rENT1 mRNA and [
3
H]-NBMPR binding sites.  They 
found that, despite the strong in situ hybridization signal for rENT1 in the hippocampus, dentate 
gyrus and cerebellum, there was a relatively low density of [
3
H]-NBMPR binding in these 
regions (Anderson et al., 1999b).  However, these differences in the distribution of ENT1 mRNA 
and the transporter protein may be explained, as protein expression does not always parallel 
mRNA concentration.  Moreover, it is possible that the ENT1 transporter protein could be 
located on the somatic, dendritic, or axon terminal plasma membranes, whereas the ENT1 
transcript is expected to be localized in cell bodies (Anderson et al., 1999b).   
A study using Western blot analysis and immunohistochemical techniques to describe the 
pattern of ENT1 and ENT2 transporter localization in the CNS (Alanko et al., 2006), describes 
findings similar to those of Anderson and colleagues.  Additionally, the study describes ENT1 as 
being located mainly on the cellular membrane, whereas ENT2-immunoreactivity indicated 
cytosolic localization of the ENT2 transporter (Alanko et al., 2006).  Recently, Nivillac et al. 
found that, in transfected MCF-7 and COS-7 cells, 70% of fluorescence tagged ENT1 that was 
transfected into cells was in the plasma membrane with the remainder localized intracellularly, 
where it is most likely undergoing processing within the secretory pathway (Nivillac et al., 
2009).  This evidence suggests that ENT1 may have a more important role in membrane 
transport of nucleosides between intracellular and extracellular regions while ENT2 may be more 
important for the transport of nucleosides between intracellular compartments.   
 Although there seems to be some species variability in the regional distribution of 
equilibrative transport proteins in the CNS, more than one study (Anderson et al., 1999a; 
Anderson et al., 1999b; Jennings et al., 2001) observed the distribution of ENT1 and ENT2 
mRNA or protein in regions of the rat and human brain that are also known to contain adenosine 
receptors.  In fact, Parkinson and co-workers showed that ENT1 and ENT2 are present in both 
cultured rat forebrain astrocytes and neurons; with ENT2 contributing 2-3 fold more to adenosine 
uptake than ENT1.  These studies emphasize the importance of equilibrative nucleoside 
transporters in the regulation of extracellular adenosine concentration, and the correlation 
between ENT1 and adenosine A1 receptor distribution suggests potential interactions and/or 
feedback between receptors and transporters.  
 Overall, the broad distribution of ENTs throughout not only the CNS, but also the body as 
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a whole, conveys the physiological importance of these transporters in the regulation of 
nucleoside homeostasis. 
  
1.2.3 Physiological relevance of equilibrative nucleoside transporters  
 
One of the main physiological functions of nucleoside transporters is in the supply of 
nucleosides for salvage pathways of nucleotide synthesis in cells that lack de novo biosynthetic 
pathways (Baldwin et al., 2004).  In addition to this, ENTs are important to the regulation of 
extracellular adenosine concentration, and thus they also influence the many processes that are 
modulated by adenosine receptor activation.   
Equilibrative nucleoside transporters have been shown to have potential therapeutic 
application in the treatment of inflammatory and neuropathic pain, as nucleoside transport 
inhibitors have been reported to potentiate opioid-mediated anti-nociception in vivo (Keil and 
Delander, 1995).  It is known that A1 receptor activation in the spinal cord has anti-nociceptive 
effects (Sawynok, 1998), and intrathecal administration of inhibitors of adenosine metabolism 
produce anti-nociception in the rat (Poon and Sawynok, 1998).  There is an abundant amount of 
ENT1 in the dorsal horn of the spinal cord and it has been shown that inhibition by NBMPR, and 
a subsequent increase in adenosine concentration, leads to pre-synaptic A1 receptor-mediated 
inhibition of glutamatergic synaptic transmission in the substantial gelatinosa (Ackley et al., 
2003).  Thus, targeting nucleoside transporters has recently been recognized as a new strategy for 
harnessing the analgesic potential of adenosine (Yan et al., 2003).   
Through the use of ENT1 knock out mice, recent studies indicate that ENT1, but not 
ENT2 (Nagy et al., 1990), has a physiological role in ethanol-mediated behaviors (Choi et al., 
2004) and the modulation of anxiety-like behavior (Chen et al., 2007).  In vitro studies show that 
ethanol stimulates adenosine signaling by inhibiting ENT1, whereas chronic ethanol exposure 
down-regulates ENT1 (Nagy et al., 1990; Mailliard and Diamond, 2004).  ENT1-null mice have 
reduced hypnotic and ataxic responses to ethanol and greater consumption of alcohol (Choi et al., 
2004).  Administration of an A1 receptor agonist restored A1 receptor inhibition of synaptic 
transmission and reduced alcohol consumption in ENT1-null mice (Choi et al., 2004).  Overall, 
increased alcohol consumption is linked to decreased levels of extracellular adenosine; 
diminished A1 receptor mediated pre-synaptic inhibition, and increased glutamate release, 
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leading to enhanced phosphorylation of CREB.  The resultant increase in expression of CRE-
regulated genes contributes to a diminished drug reward and thereby drives drug self-
administration.     
Nucleoside transporters also hold clinical significance as they are known to be abundant 
in cancerous tissue and are harnessed as a means for the cellular uptake of anticancer and 
antiviral drugs (King et al., 2006). Inhibitors of ENTs, dipyridamole and dilazep, are also used in 
the treatment of heart and vascular disease, as they have been shown to substantially increase the 
cardiovascular effects of adenosine (Dennis et al., 1996).  Additionally, post-ischemic inhibition 
of nucleoside uptake by ENTs has also been shown to elevate the concentration of adenosine in 
the brain and prevent against ischemia-induced cell loss of hippocampal CA1 neurons in the rat 
(Parkinson et al., 2000).  This evidence provides support that ENTs might play an important role 
in determining the extent of neuronal damage following a stroke.  
 
1.2.4 Regulation of equilibrative nucleoside transporters in the CNS 
 
Nucleoside transporters mediate the transfer of adenosine across cell membranes and 
therefore are largely responsible for the regulation of intracellular and extracellular adenosine.  
While there is an appreciable amount of data describing the regulation of other membrane 
transporters (Baldwin et al., 1995), little is known about the regulation of ENTs, particularly 
within the CNS.  However, a variety of factors have been shown to influence the activity and 
expression of nucleoside transporters, including hormones, nutrients, adenine nucleotides, and 
intracellular signaling pathways (Kong et al., 2004).   
   
1.2.4.1 ENT activity is dependent on cell cycle and growth 
 
Within the literature, most studies looking at the regulation of ENTs suggest that ENT1 
plays a role in cell proliferation, being responsible for constitutive nucleoside supply.  In cultured 
murine bone marrow microphages, proliferation induced by M-CSF (macrophage colony-
stimulating factor) resulted in the up-regulation of ENT1 mRNA and protein, but it had no effect 
on ENT2 expression (Soler et al., 2001).  Other factors that stimulate cell proliferation and 
metabolism may also modulate pathways that regulate the uptake of nucleosides to accommodate 
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increased use of nucleosides in nucleic acid synthesis and metabolic pathways, which is 
supported by evidence showing that ENT1 is highly expressed in tumors (Molina-Arcas et al., 
2009).  Thyroid hormones are also important to the regulation of adenosine transport, as 
synaptosomal preparations from the brain stem of hypothyroid rats show reduced ENT1 
adenosine transport, and in cultured chromaffin cells T3 (triiodothyronine) increased the number 
of nucleoside transporters and stimulated adenosine transport (Fideu and Miras-Portugal, 1992; 
Fideu et al., 1994).  Additionally, it has been well documented that extracellular glucose and 
insulin differentially regulate the activity and expression of ENT1 and ENT2, and that the 
mechanisms of regulation may involve endothelial NO synthase, PKC, and mitogen activated 
protein kinases (MAPK) in different tissues. (Podgorska et al., 2005) 
 
1.2.4.2 Regulation of ENTs by protein kinases 
 
An increasing amount of literature suggests that direct post-translational modification by 
intracellular kinases is a possible mechanism for regulating the activity of ENTs.  A study by Coe 
et al. 2002, using two human cancer cell lines (MCF-7 and HeLa) shows the acute stimulation of 
PKC causes a rapid increase in hENT1 nucleoside uptake, and that PKC isoforms δ and/or ε are 
responsible for this effect (Coe et al., 2002).  This acute stimulation of PKC leads to an increase 
in hENT1-dependent nucleoside uptake that is suggested to correlate with an overall increase in 
the activity of the transporters at the plasma membrane, but does not appear to correlate with 
trafficking of proteins from intracellular stores since there was no significant difference in NBTI 
binding in purified plasma membranes, compared to their control (Coe et al., 2002).  This is 
some of the first evidence that hENT1 is subject to rapid regulation by intracellular signaling 
pathways, however the underlying mechanisms responsible for these rapid effects are not clear 
but studies of other transporters suggest several possible pathways, including direct 
phosphorylation (Coe et al., 2002).  
 PKC has also been implicated in long-term regulation of ENTs, since there is a PMA-
dependent (phorbol myristyl acetate) decrease in ENT1 nucleoside transport in HL-60 cells (a 
leukemic cell line) (Sokoloski et al., 1991; Lee, 1994).  Similarly, in cultured bovine chromaffin 
cells, PMA treatment decreases adenosine transport (Delicado et al., 1991). It has also been 
shown in chromaffin cells that purinergic P2Y-receptor agonists inhibited adenosine transport, 
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likely through PKC activation (Sen et al., 1993). Whether the decreased transport rate by PKC 
activation is due to direct modification of the transporter protein or internalization of these 
transporters into intracellular compartments is unknown. Interestingly, a study conducted by the 
same group in bovine adrenal endothelial cells, showed that PKC had no effect on the ENT1 
transporter in these cells (Sen et al., 1996). Coe et al showed that, in both HeLa and MCF-7 cells, 
long-term treatment with PMA and down-regulation of PKC is associated with a decrease in 
ENT1 nucleoside transport, this is in agreement with numerous other studies and suggests the 
possibility of transcriptional regulation (Coe et al., 2002).  
In some cases, it seems as though the regulation of transporter activity by PKC is 
contradictive which suggests that there are many mechanisms regulating nucleoside transport 
function and that it is cell and tissue specific.   
 PKC is not the only protein kinase known to take part in the regulation of ENTs.  Recently, 
Huang et al. showed that many protein kinase inhibitors, including those for PKC and p38 
MAPK, inhibit ENT1, and possibly ENT2, transporter activity.  However, Huang et al attributed 
this to the direct interaction with the NBMPR binding site in the transporter protein, rather than 
by kinase-dependent pathways (Huang et al., 2004).   
 
1.2.4.3 CK2 modulation of ENTs 
  
 The presence of a number of kinase consensus sites within the ENT1 (and ENT2) protein, 
including consensus sites for PKC, PKA, CK1 and CK2, suggests the possibility of direct 
phosphorylation as a means of transporter regulation (Reyes et al.; Griffiths et al., 1997b).  Two 
splice variants of mouse ENT1 (mENT1) were simultaneously identified by the Handa and 
Hammond laboratories (Kiss et al., 2000; Handa et al., 2001).  The two variants, arising from 
alternate splice sites at the end of exon 7, contain differences in the region of the large 
intracellular loop between transmembrane (TM) regions six and seven (Handa et al., 2001).  The 
smaller variant has a 6bp deletion in the large intracellular loop, resulting in the loss of Lys-255 
and Gly-256, and conversion of the serine at position 254 to an arginine.  The conversion of Ser-
254 to arginine results in the negation of one of the accepted protein kinase CK2 phosphorylation 
consensus sites (Handa et al., 2001).  Loss of this CK2 consensus site suggests that the two 
variants may differ in their susceptibility to phosphorylation by CK2.   
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In a recent study by Stolk et al., human osteosarcoma cells, which possess both ENT1 and 
ENT2 transport activity, transfected with catalytically active or inactive CK2  and CK2  
subunits of CK2 were used to assess the effects of CK2 manipulation on nucleoside transporter 
activity.  Their findings suggest that the inhibition of CK2 activity, by induction of the 
catalytically inactive CK2  subunit, lead to enhanced expression of ENT1 on the plasma 
membrane and functional activation of the transporter.  They also found that the inhibition of 
CK2 activity by induction of inactive CK2  reduced both the activity and mRNA levels of 
ENT2.  This suggests that ENT1 and ENT2 may be differentially modulated by CK2 and that the 
reduction in ENT2 activity is caused by an attenuation of ENT2 transcription, while the increase 
in ENT1 expression and activity is mediated by the post-translational action of CK2.  
Importantly, this study suggests that CK2-mediated phosphorylation of the ENTs regulates their 
localization on the plasma membrane and/or their trafficking between subcellular membrane 
compartments (Stolk et al., 2005). 
In another study, looking at the modulation of mENT1 by CK2 in PK15 (nucleoside 
transporter deficient) transfected cells, it was found that CK2 phosphorylated ENT1 at Ser-254, 
and that phosphorylation at this site causes changes in the sensitivity of the transporter to the 
inhibitor NBMPR as well as changes in the number of functioning transporters at the plasma 
membrane.  In this study it was found that the inhibition of CK2-mediated phosphorylation of the 
transporter at Ser-254 had the same functional effect as the actual loss of Ser254 in the shorter 
mENT1 variant, implying that Ser-254 is constitutively phosphorylated by CK2.  Here, it was 
shown that CK2 inhibition leads to a down-regulation in the activity of ENT1 and a reduction in 
the number of transporters that are active at the plasma membrane.  It is suggested by the authors 
that the reduction in the activity of ENT1, induced by treatment with the CK2 inhibitor TBB, 
reflects an alteration in the intracellular trafficking of this ENT1 variant such that less of the 
protein is recycled to the plasma membrane, as opposed to direct effect on ENT1 internalization. 
(Bone et al., 2007)  
The opposite effect of CK2 inhibition seen in PK15 cells and the human osteosarcoma 
cells may reflect cell line, endogenous or recombinant ENT1, or CK2 isoform expression 
differences in the two experimental models (Bone et al., 2007), however, it is evident from both 
studies that the inhibition of CK2 influences the function and expression of ENTs. 
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1.2.4.4 Chronic hypoxia regulates ENT mRNA and protein levels 
 
There are two studies that look at the effects of chronic exposure to hypoxia on ENTs 
(Kobayashi and Millhorn, 2001; Chaudary et al., 2004), which suggest that ENT1 gene 
expression may be sensitive to hypoxic regulation in both cardiac and neural tissue.  The first 
study investigates the mechanisms of adenosine production, release, and uptake during chronic 
hypoxia in PC12 cells, a cell line that is used as a model of neuronal cellular physiology. In this 
study, the authors report that chronic hypoxia down-regulates the function of adenosine-
metabolizing enzymes (adenosine kinase and adenosine deaminase), whereas it up-regulates the 
function of adenosine-producing enzymes (cytosolic and ecto-5’-nucleotidases) (Kobayashi and 
Millhorn, 2001).  It was also determined that chronic hypoxia down-regulates rENT1 mRNA 
without significantly changing the mRNA level of rENT2.  In agreement with this, Chaudary et 
al. 2004 determined that PKCε regulates mENT1 activity in HL-1 cardiomyocytes and a down-
regulation of PKCε during chronic hypoxia results in a down-regulation of mENT1 protein and 
mRNA.  They proposed that chronic hypoxia decreases mENT1 dependent adenosine uptake, in 
part, by a decrease in the amount of mENT1 protein at the membrane.  In addition to a down-
regulation in ENT1-mediated adenosine transport, they found evidence that suggests mENT2 is 
also down-regulated by hypoxia. These hypoxia-induced modifications in adenosine metabolism 
and transport seem to favor an increase in the extracellular concentration of adenosine, which has 
been shown to be neuroprotective during hypoxic insult to the brain and other tissues.   
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Figure 1.3.  Regions of substrate interaction and points of post-translational modification in ENT1 and ENT2. 
Glycosylation sites are indicated by the blue circles, and correspond to Asn48 (m/hENT1), Asn47 and Asn56 
(m/hENT2) (Kiss et al., 2000).  CK2 phosphorylation consensus sites are depicted by green circles and correspond to 
Thr248 (rENT1), Ser254 (r/m/hENT1), Thr235 (rENT2), Thr236 (mENT2) and Ser270 (hENT2). PKC 
phosphorylation consensus sites are denoted by the red circles, which correspond to Ser109 and Thr274 
(r/m/hENT1), and Ser95 and Thr223 (r/mENT2) (Data was obtained from NetPhosK and NCBI GenPept). TM 
regions 5-6 (yellow) are important in the recognition of nucleobases substrates (hENT1) (Baldwin et al., 2004), and 
TM regions 3-6 (green and yellow) are major sites of NBMPR interaction (Kong et al., 2004). 
 
 
1.3 Protein kinase CK2  
 
Protein kinase CK2, formerly known as casein kinase II, is a highly conserved, cyclic 
nucleotide-independent serine/ threonine protein kinase that is ubiquitously distributed in 
eukaryotic organisms (Blanquet, 2000; Pinna, 2002; Litchfield, 2003).  CK2 is one of two casein 
kinases that have been found in many different cell types.  There are four criteria that are used to 
differentiate between the two known casein kinases; these include their substrate specificity for 
nucleotide triphosphates, specificity for phosphate-accepting amino acids in casein, and the 
effects of heparin and 2,3-diphosphoglycerate on enzyme activity. The type 1 enzyme, CK1, uses 
only ATP as a phosphate donor, modifies serine residues, and heparin or 2,3-diphosphoglycerate 
does not alter its activity.  In contrast, CK2 is able to use GTP or ATP as phosphate donors, 
modifies both serine and threonine residues, and can be inhibited by heparin and 2,3-
diphosphoglycerate (Blanquet, 2000). 
 CK2 is a holoenzyme that is generally composed of two catalytic subunits (  and/or ) 
and two regulatory subunits ( ) that can associate to form many distinct heterotetramers, 
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although free catalytic subunits can be present under some circumstances (Blanquet, 2000; Pinna, 
2002; Litchfield, 2003).  The exact function of the  subunit is not known, but it is suggested that 
it is important for stability, activity, and specificity of the enzyme (Blanquet, 2000; Litchfield, 
2003), and it is suggested that the catalytic activity of the holoenzyme is higher than that of the 
isolated subunits (Pinna, 2002).   
 For a long time, it was believed that CK2 was unregulated in the cell; however there are 
now a number of reports that show the activity of CK2 can be regulated in neuronal and non-
neuronal cells (Blanquet, 2000).  In neuronal tissue, CK2 activity has been shown to change in 
response to treatment with brain-derived neurotropic factor (BDNF) (Blanquet, 1998), the 
polyamines spermine and spermidine (Tuazon and Traugh, 1991; Pinna, 2002), and during the 
induction of NMDA-dependent hippocampal LTP (Charriaut-Marlangue et al., 1991).  It has also 
been shown that CK2 activity is reduced after periods of brief ischemia (Hu et al., 1993) and in 
response to chronic ethanol exposure (Haviryaji and Vemuri, 1997).    
 CK2 has a large number of substrates that possess the phosphorylation consensus sequence 
characterized by multiple acidic residues surrounding the phosphoacceptor residue, which can be 
serine, threonine or, in some cases, tyrosine (Pinna, 2002).  The large numbers of known CK2 
substrates include a multitude of transcription factors, many of which are nuclear proteins 
implicated in gene expression and transcription, as well as translational factors and a lot of other 
proteins with various functions in cell signaling (Pinna, 2002). 
 CK2 activity is present in many brain areas (cortex, septum, hippocampus, caudate-
putamen, thalamus, olfactory bulb, cerebellum, and spinal cord), and immunostaining has 
revealed that CK2 is primarily associated with neuronal populations (Girault et al., 1990).  
Looking at subcellular CK2 activity, it was found that in the adult rat caudate-putamen, 45% of 
total CK2 activity existed in the cytosol, one-third of the activity was in the crude synaptosomal 
fraction, and 10% in the nuclear pellet (Girault et al., 1990).  Subfractionation of the crude 
synaptosomal pellet further revealed that most of the CK2 activity in this fraction was associated 
with synaptosomes (Girault et al., 1990), indicating that CK2 is present in nerve terminals.  
 CK2 appears to participate in many neurophysiological functions, including neuronal 
differentiation, cell proliferation, and the pathogenesis of neurological diseases including 
schizophrenia and Alzheimer’s disease (Blanquet, 2000).  There is an increasing amount of 
evidence that suggests that CK2 participates in synaptic plasticity and memory formation.  CK2 
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activity is transiently increased after high frequency stimulation, during the induction of 
hippocampal LTP (Charriaut-Marlangue et al., 1991), and BDNF, which is released in an 
activity-dependent manner and is important for synaptic plasticity, activates CK2 in a 
concentration dependent manner (Blanquet, 1998).  Lieberman and Mody 1999, also 
demonstrated CK2 as being a selective regulator of NMDA channel gating in neurons.  They 
showed that CK2 caused a prolongation of NMDA channel opening and that channel activity 
could be up-regulated by spermine through the stimulation of CK2, or down-regulated by 
calcineurin following activation of calcium/calmodulin (Lieberman and Mody, 1999).  In 
addition to this, it was recently found that CK2 inhibition prevented the induction of NMDA 
receptor-dependent LTP, but not NMDA receptor-independent LTP (Kimura and Matsuki, 2008).  
It was suggested that this happens via selective regulation of synaptic NMDA receptor activity, 
but not extra-synaptic NMDA receptor activity, whose activation is sufficient to induce LTD.  
Recently, it was determined that CK2 phosphorylates NR2B, but not NR2A, subunits of the 
NMDA receptor, causing the endocytosis and removal of NR2B subunits from the neuronal 
synapse, and promoting the synaptic expression of NR2A, which is now thought to be important 
in the induction of LTP in young animals (Sanz-Clemente et al.).       
 CK2 has also been implicated as a neuroprotectant after hypoxic insult to the brain (Kim et 
al., 2009).  It was determined that there is a reduction in CK2 activity (caused by a reduction in 
the catalytic subunit proteins CK2  and CK2 ) after oxygen glucose deprivation and middle 
cerebral artery occlusion, and that loss of CK2 activity triggers ROS production via NADPH 
oxidase and enhanced neuronal death during ischemic injury (Kim et al., 2009). 
 
1.4 AMPAergic glutamate receptors 
 
Glutamate is the major excitatory neurotransmitter in the brain; its effects are mediated by 
the activation of ionotropic and metabotropic receptors (Santos et al., 2009).  AMPA receptors, a 
type of ionotropic glutamate receptors, mediate fast synaptic transmission at excitatory synapses 
in the CNS and are crucial during neuronal development, synaptic plasticity and structural 
remodeling (Liu and Zukin, 2007).  AMPA receptors are tetrameric assemblies of subunits 
GluR1-4, which are encoded by separate genes and are differentially expressed throughout the 
CNS (Liu and Zukin, 2007).  The presence of GluR2 in heteromeric AMPA receptors governs 
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the channel impermeable to Ca
2+
 (Liu and Zukin 2007).  Under physiological conditions, neurons 
of the hippocampus express GluR2-containing, Ca
2+
-impermeable AMPA receptors (Liu and 
Zukin, 2007).  Because these cells do not express high levels of Ca
2+
-binding proteins or fast 
local Ca
2+
-extrusion pumps, an acute loss of GluR2 would be expected to contribute to enhanced 
pathogenicity of endogenous glutamate and vulnerability to neuronal insults (Liu and Zukin, 
2007).  Ischemic insults are thought to cause remodeling of AMPA receptor subunits and a long-
lasting switch in AMPA receptor phenotype, from GluR2-containing to GluR2-lacking receptors 
(Liu and Zukin, 2007).  Thus, global ischemia, such as that which occurs during a stroke, causes 
delayed neuronal death, primarily of hippocampal CA1 neurons, which has been suggested to be 
caused by increased Ca
2+
 entry through AMPA receptors and subsequent excitotoxicity (Gorter et 
al., 1997).   
As mentioned previously, it is well known that there is an increase in the level of 
extracellular adenosine during ischemia, and preliminary findings from our research group point 
to a novel mechanism whereby the glutamate AMPA receptor subunits undergo redistribution 
during prolonged adenosine A1 receptor activation.  However, the relationship between the rise 
in extracellular adenosine and AMPA receptor subunit remodeling is not yet well understood.  
Two serine/threonine kinases that are widely expressed in the brain, p38 MAPK and c-Jun N-
terminal kinase (JNK), have recently been shown by Brust and colleagues to be an important link 
between adenosine A1 receptor activation and the inhibition of synaptic transmission pre-
synaptically.  It has been shown that adenosine A1 receptor activation increased the 
phosphorylation and activity of p38 MAPK and JNK, and that this increased activity initiates a 
signaling cascade that inhibits glutamate release from pre-synaptic terminals (Brust et al., 2006; 
Brust et al., 2007).  The synaptic depression induced by receptor A1 activation was attenuated by 
JNK inhibition as well as p38 MAPK inhibition.  The inhibition of p38 MAPK also inhibited 
adenosine A1 receptor activation dependent phosphorylation of JNK (Brust et al., 2007).  A role 
for p38 MAPK and JNK in the redistribution of GluR2 receptors was suggested in a study done 
on the responsiveness of AMPA receptors in the nucleus accumbens after removal of repetitive 
cocaine treatment (Boudreau et al., 2007).  It was shown that phosphorylation of JNK following 
cocaine challenge was inversely related to surface/intracellular GluR1 and GluR2 ratios.  Also, 
after saline challenge, the increased phosphorylation of p38 MAPK correlated with a decrease in 
the surface/intracellular ratio of GluR1 and GluR2 (Boudreau et al., 2007).  Therefore, based on 
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the evidence that suggests the involvement of p38 MAPK and JNK in both adenosine A1 
signaling cascades pre-synaptically as well as in AMPA receptor subunit translocation, a possible 
link between adenosine A1 receptor activation and AMPA receptor trafficking may exist.  Thus, 
the persistent activation of adenosine A1 receptors could lead to AMPA receptor subunit 
redistribution and a novel form of synaptic depression. 
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CHAPTER 2 
 
HYPOTHESIS AND OBJECTIVES 
 
 
The aim of this thesis is to examine the localization of equilibrative nucleoside transport 
proteins 1 and 2 (ENT1 and ENT2) in response to the inhibition of protein kinase CK2.  
Furthermore, the localization of specific glutamate receptor subunits (GluR1 and GluR2) will be 
assessed, as this may be an indicator of the importance of ENT regulation in synaptic signaling.  
 
Specific Aims: 
 
1. To observe changes in membrane localization of ENT1 and ENT2 induced by CK2 inhibition.  
Equilibrative nucleoside transporters (ENT1 and ENT2) contain strong consensus sites 
for CK2 phosphorylation and it has been suggested that CK2-induced phosphorylation of ENTs 
may increase nucleoside transport activity and/or membrane localization (Kiss et al., 2000; 
Handa et al., 2001; Stolk et al., 2005; Bone et al., 2007).  CK2 mediated phosphorylation of 
ENTs would thus provide a novel mechanism for the regulation of extracellular adenosine tone 
and synaptic transmission in the brain.  However, it remains unclear whether this 
phosphorylation of ENTs by CK2 is physiologically significant. Therefore the first objective of 
this thesis is to observe the membrane localization of ENT1 and ENT2 in response to CK2 
inhibition.  
 
Hypothesis: 
The inhibition of CK2 activity, through the prolonged incubation of hippocampal tissue 
slices with CK2 inhibitors DMAT, TBB and DRB, will cause a reduction in the surface 
localization of ENT1 and ENT2.  
 
2. To investigate any changes in the membrane localization of AMPA receptor subunits, GluR1 
and GluR2, induced by the inhibition of CK2 activity.  
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It has been demonstrated that ischemic events, during which there is a rise in extracellular 
adenosine, can cause a remodeling of AMPA receptor subunits such as to allow for greater Ca
2+
 
permeability of the cell (Gorter et al., 1997; Liu and Zukin, 2007).  However, the relationship 
between the rise in extracellular adenosine and the AMPA receptor subunit remodeling is not yet 
well understood.  Preliminary findings from our research group points to a novel mechanism 
whereby the glutamate AMPA receptor subunits undergo redistribution during prolonged 
adenosine A1 receptor activation.  If CK2-mediated phosphorylation is important for the surface 
localization of ENTs, inhibition CK2 activity may lead to a rise in extracellular adenosine 
concentration and a subsequent redistribution of AMPA receptor subunits.  Therefore, the second 
objective of this thesis is to determine whether CK2 inhibition also alters the membrane 
localization of GluR1 and GluR2 AMPA receptor subunits.  
 
Hypothesis:  
 Inhibition of CK2 activity leads to a reduction in the surface localization of AMPA 
receptor subunits GluR1 and GluR2. 
 
3.  Since it is known that the concentration of extracellular adenosine can vary with temperature, 
which may be attributed to the altered activity of the ENT2 adenosine transporter (Dunwiddie 
and Diao, 2000), the third objective of this thesis is to determine whether variation in the 
temperature that the experiments are conducted at makes ENT1 or ENT2 more or less susceptible 
to regulation by direct inhibition with ENT inhibitors.     
 
Hypothesis:  
 Changing the temperature that the experiments are performed at does not affect the extent 
to which direct ENT inhibition changes the surface localization of ENT1 or ENT2.   
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CHAPTER 3 
 
MATERIALS AND METHODS 
 
3.1 Hippocampal slice preparation 
 
Sprague-Dawley rats at postnatal day 18-30 (P18-30) (Charles River, Canada) were 
anesthetized with halothane and immediately decapitated according to protocols approved by the 
University Committee of Animal Care and Supply (UCACS).  Brains were readily extracted and 
placed in ice-cold oxygenated dissection medium containing the following (in mmol/L): 87 
NaCl, 25 NaHCO3, 25 glucose, 75 sucrose, 2.5 KCl, 1.25 NaH2PO4, 7.0 MgCl2, and 0.5 CaCl2.  
Hippocampal slices (400 m thick) were cut using a vibrating tissue slicer (Leica VT1200S) and 
maintained for 1 hr at either room temperature (22-24 C) or 35 C (water bath) in artificial 
cerebro-spinal fluid (aCSF) containing the following (in mmol/L): 126 NaCl, 2.5 KCl, 2.0 
MgCl2, 1.25 NaH2PO4, 26 NaHCO3, 10 glucose, 2.0 CaCl, and aerated with 95% O2/5% CO2.  
Hippocampal slices prepared from five animals were used for each experiment day (independent 
experiment).  Hippocampal slices were then incubated, with shaking, either at room temperature 
or 35 C in various treatments: DPY (10 mol/L), DMAT (5 mol/L), TBB (10 mol/L), DRB 
(100 mol/L), CPA (500nmol/L) or NBTI (10nmol/L or 100nmol/L) for 1.5 hr (CPA for 90min, 
45min or 30min).  DMSO was used as a vehicle control.  The tissue was lysed and separated into 
membrane and cytosolic fractions, whole cell, or into synaptosomal fractions (see below).    
   
3.2 Drugs 
 
Dipyridamole (DPY), 2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole (DMAT), 
4,5,6,7-tetrabromo-1H-benzotriazole (TBB), 5,6-dichloro-1-( -D-ribofuranosyl) benzimidazole 
(DRB), adenosine N
6
-cyclopentyladenosine (CPA), and S-(4-Nitrobenzyl)-6-thioinosine (NBTI) 
were all obtained from Sigma-Aldrich and made up as stock solution before being added to 
aCSF.  The final concentration of DMSO was always <0.1%.   
NBTI and DPY are structurally distinct ENT inhibitors that bind with high affinity to 
sites closely adjacent to the nucleoside recognition site (Young et al., 2008).  NBTI binds with 
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high affinity (Ki 0.1-10 nM) to ENT1, but has little effect on ENT2 at concentrations less than 1 
M (Baldwin et al., 1999).  Alternately, DPY, while displaying large sensitivity differences 
among species, inhibits both rat ENT1 and ENT2 with similar affinity (Ki 5-30 M) (Griffith and 
Jarvis, 1996). 
 
3.3 Membrane and cytosolic fractionation 
 
Membrane and cytosolic fractions were prepared as previously described (Brust et al., 
2006; Brust et al., 2007).  The hippocampal tissue slices were lysed in a solubilization buffer (30 
min) that contained 50mmol/L Tris (pH8.0), 150mmol/L NaCl, 1mmol/L EDTA, 1mmol/L NaF; 
protease inhibitors (Sigma): 1mmol/L PMSF, 10 g/ L aprotinin, 10 g/mL pepstatin A, 
10 g/mL leupeptin, 2mmol/L Na3VO4, 20mmol/L sodium pyrophosphate, 3mmol/L benzamidine 
hydrochloride, and 4mmol/L glycerol 2-phosphate.  The tissue homogenates were then 
centrifuged at 1,000 g (5 min at 4 C) to remove cellular debris.  Membrane and cytosolic 
fractions were separated by centrifugation at 13,000 g for 1 hr at 4 C by omitting the detergent 
from the solubilization buffer.  Proteins from the particulate (membrane) fraction were resolved 
in normal solubilization buffer (as above plus detergent, 1% NP-40) after removal of cytosolic 
extract (supernatant). 
 
3.4 Whole cell fractionation 
  
For whole cell fractionation, the lysis of hippocampal tissue slices was carried out as for 
membrane and cytosolic fractionation except 1% NP-40 was added to initial solubilization 
buffer.  Following tissue lysis, samples were centrifuged at 1,000 g for 5min.  Proteins from the 
supernatant (whole cell fraction) were then resolved in the solubilization buffer containing 1% 
NP-40.  This was achieved by vortexing the sample every 5min for 20min.  Protein concentration 
of each sample was then determined, as described below.    
 
3.5 Synaptosomal fractionation 
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Synaptosomes were prepared from the hippocampal tissue slices (mentioned above) 
following previously published methods (Hammond and Clanachan, 1985; Parkinson et al., 
2009).  Hippocampal tissue slices were homogenized in 10 volumes ice-cold 0.32M sucrose and 
centrifuged at 1000 g for 10 min at 4 C.  The pellet was washed twice and the pooled 
supernatants were centrifuged for 55mins at 17,000 g (4 C) to obtain crude synaptosomal pellet.  
The pellet was re-suspended in HEPES buffer, containing the following (in mmol/L): 100 NaCl, 
25 glucose, 68.3 sucrose, 5.3 KCl, 1.8 CaCl, 1.0 MgSO4, 20 HEPES; pH 7.4.   
 
3.6 Western blot analysis 
 
All protein concentrations of the samples were determined by a dye binding method 
(Bradford assay), using bovine serum albumin as a standard.  The Bradford assay was carried out 
using protein assay dye from BioRad and measured using a photospectrometer (Novaspec Plus 
visible spectrophotometer from Biochrom). Hippocampal homogenates were diluted with 1X 
Laemmli sample buffer (BioRad) plus 100mmol/L dithiothreitol (DTT; Sigma) and boiled for 10 
min.  30-50µg/lane proteins were separated on 10% polyacrylamide gel (180V for ~1 hr) and 
electrotransferred to polyvinylidene fluoride (PVDF) membranes (0.4A for 3 hr at 4 C) 
(Millipore).  The membranes were incubated overnight (4°C) with the appropriate primary 
antibody diluted in 5% non-fat milk in TBST containing 0.025% sodium azide.  The primary 
antibody dilutions are as follows:  
   
Table 3.1 Primary antibody descriptions  
Primary Antibody Source Dilution Sequence  
Polyclonal rabbit anti-ENT1 Millipore 1:1000  mENT1 
Polyclonal rabbit anti-ENT1 Abcam 1:1000 250-350 of hENT1 
Polyclonal rabbit anti-ENT2 Abcam 1:1000 350-450 of hENT2 
Polyclonal rabbit anti-GluR1 Millipore 1:1000 276-287 of rGluR1 
Polyclonal rabbit anti-GluR1 Abcam 1:1000 850-C-terminus of hGluR1 
Monoclonal mouse anti-GluR2 Millipore 1:1000 175-430 of mGluR2 
Polyclonal rabbit anti-synapsin 1a/b Santa Cruz 1:1000 C-terminus of hSynapsin 1a/b 
Monoclonal mouse anti-GAPDH Millipore 1:2000 Clone 6C5 rGAPDH 
Note: h, human; r, rat; m. mouse. 
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Following four washes (15 min) with TBST, the membranes were incubated with rabbit, mouse 
or goat horseradish peroxidase-conjugated secondary antibody against IgG (1:1000; Santa Cruz, 
1:3000 for GAPDH) in 5% non-fat milk (1 hr, room temperature).  The membranes were then 
washed 4X (15 min) with TBST, and proteins were visualized using enhanced 
chemilluminescence (ECL).   
 
3.7 Immunoprecipitation  
 
To examine interactions of ENT1 (Abcam) and ENT2 (Abcam) with GluR1 (Abcam) and 
GluR2 (Millipore) AMPA receptor subunits, immunoprecipitation was performed by first 
incubating
 
500 g extract from hippocampal homogenates with 4 g of the antibody 
corresponding to the protein being immunoprecipitated (overnight; 4°C).  Then protein A/G 
PLUS agarose (Santa Cruz) beads
 
were added to the homogenates for either an additional 3 hours 
(at room temperature) or overnight (4°C) to collect the immunoprecipitates.  Agarose beads were 
then collected by pulse spins,
 
and washed four times with wash buffer (solubilization buffer
 
containing 0.1% NP-40).  Proteins from the agarose beads were
 
eluted with 65 µl of 1X Laemmli 
sample buffer, boiled for 10 min, and resolved in polyacrylamide gels.  Proteins
 
were then 
electrotransferred to PVDF membranes and proteins were visualized using ECL.   
 
3.8 Protein densitometry and statistics 
 
Protein densitometry analysis of Western blots was performed using QuantityOne 
software from BioRad and ImageJ software from NCBI.  Protein signals were quantified by 
normalizing all bands with the GAPDH protein band signals; protein bands for each of the 
treatments were then normalized to their control.  Significant differences between population 
means were assessed using a one-way ANOVA followed by a Student-Newman-Keuls post-hoc 
statistical test, where appropriate, with a confidence level of p<0.05.  Results are presented as 
mean ± standard error of the mean (SEM).  Each Western blot, or repetition, was considered to 
be n; multiple n values were taken from each experiment day, or independent experiment.  All 
statistical analyses were performed using the software program INSTAT 2. 
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CHAPTER 4 
 
RESULTS 
 
 
4.1 Effect of protein kinase CK2 inhibition on ENT1 and ENT2 protein localization 
 
Little is known about how the activity and/or localization of ENTs are controlled in the 
hippocampal brain region.  However, it has been shown that the localization of nucleoside 
transporters is subject to regulation by kinase-dependent pathways.  Both activators and 
inhibitors of PKC, PKA and CK2 have been shown to alter the transport function and membrane 
localization of nucleoside transporters in a variety of cell lines (Lee, 1994; Coe et al., 1996; Coe 
et al., 2002; Stolk et al., 2005; Bone et al., 2007).  Indeed, a mouse ENT1 splice variant that is 
lacking CK2 phosphorylation consensus sites has been shown to have a reduced concentration of 
functional ENT1 transporters at the level of the plasma membrane, compared to its larger variant 
(Handa et al., 2001; Bone et al., 2007). 
So while the manipulation of PKC and CK2 activity has been shown to modify ENT1 
plasma membrane localization and cellular nucleoside transport capacity (Coe et al., 2002), 
whether the regulation of ENTs by CK2 phosphorylation in the hippocampus is physiologically 
significant remains unclear.  Multiple Western blot experiments, measuring the protein level of 
each nucleoside transporter (ENT1 and ENT2), were performed to examine the effect of protein 
kinase CK2 inhibition on membrane localization of ENTs.   
 
4.1.1 ENT1 membrane localization 
  
 Firstly, the effect of the inhibition of CK2 function, by DMAT, TBB and DRB, on the 
surface localization of ENT1 in native hippocampal tissue slices was determined.  The polyclonal 
antibody against ENT1 (Millipore) recognized protein bands at approximately 83 (Figure 4.1C), 
60 and 50 kDa (Figure 4.1A, C).  Although the ENT1 protein is most often detected around 50 
kDa, it has been observed to be anywhere between 40-62 kDa, with the differences attributed to 
differential glyclosylation (Reyes et al.; Torres et al., 1992; Yao et al., 1997; Musa et al., 2002).  
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The protein band observed at approximately 83 kDa has recently been suggested by other groups 
to represent an ENT1 protein dimer or ENT1 protein complex (Reyes et al.; Torres et al., 1992), 
however it was not analyzed in this study due to the high saturation of this band in most of the 
blots that were obtained, making it difficult to measure the densitometry accurately. Minor bands 
of lower molecular mass seen in Figure 4.2A probably represent degradation products of the 
rENT1 polypeptide. 
 Densitometry analysis of the 60 kDa band revealed that CK2 inhibition with DMAT 
(5 mol/L), TBB (10 mol/L) and DRB (100 mol/L) caused significant reduction in the amount 
of protein localized at the level of the plasma membrane (p<0.01).  Compared to the control 
treatments, the amount of ENT1 in the hippocampal cell membrane fraction was reduced by 43 
% (0.56855 +/- 0.08351), 33 % (0.66971 +/- 0.09337) and 38 % (0.61948 +/-0.0925) by DMAT, 
TBB and DRB, respectively (Figure 4.1B).  Analysis of the cytosolic fraction of the tissue 
samples revealed no significant change in the cytosolic localization of ENT1 among the 60 kDa 
band after treatment with CK2 inhibitors, when compared to the control (Figure 4.2B).    
Analysis of the 50 kDa protein band showed that there were no significant changes in the 
membrane or cytosolic localization of ENT1 in the presence of the CK2 inhibitors (Figure 4.1D, 
Figure 4.2C).  
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Figure 4.1.  CK2 inhibition decreases ENT1 localization in membrane fractions.  Hippocampal slices were 
exposed to either control DMSO, DMAT (5 M), TBB (10 M) or DRB (100 M) for 1.5hr.  The membrane and 
cytosolic fractions of hippocampal homogenates were separated by centrifugation and used for Western Blot 
analysis. A. Inhibition of CK2 causes internalization of ENT1 in membrane fractions. Top.  Full-length 
representative Western blot showing ENT1 bands near 83 kDa, 60 kDa and 50kDa, and the GAPDH protein bands 
(~37 kDa) used to normalize ENT1 signals (Bottom).   C. Top.  Partial Western blot showing ENT1 bands near 60 
kDa and 50 kDa. Bottom.  GAPDH protein bands (~37 kDa) used to normalize ENT1 signals.  B, D.  Quantitative 
representation of multiple Western blots showing inhibition of CK2 caused internalization of the 60 kDa ENT1 
protein in membrane fraction (p<0.01, one-way ANOVA), but not the 50 kDa protein (p=0.1936, one-way 
ANOVA).  Values are means ± SEM [ENT1 60 kDa- DMSO (n=8), DMAT (n=7), TBB (n=6) and DRB (n=8); from 
three independent experiments] [ENT1 50 kDa- DMSO (n=10), DMAT (n=10), TBB (n=10), DRB (n=9); from three 
independent experiments]. **p<0.01 vs. control.  
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Figure 4.2.  CK2 inhibition does not alter cytosolic localization of ENT1.  A.  Inhibition of CK2 does not cause 
internalization of ENT1 in cytosolic fractions. Top. Representative Western blot showing ENT1 bands near 50 kDa 
and 60 kDa.  Bottom. GAPDH protein bands (~37 kDa) used to normalize ENT1 signals.  B-C.  Quantitative 
representation of multiple Western blots showing inhibition of CK2 did not cause a significant change in the 
localization of the 60 kDa or 50 kDa ENT1 proteins (p=0.9675 and p=0.9852, respectively, one-way ANOVA).  
Values are means ± SEM [ENT1 60 kDa- DMSO (n=5), DMAT (n=5), TBB (n=4) and DRB (n=5); from three 
independent experiments] [ENT1 50 kDa- DMSO (n=5), DMAT (n=4), TBB (n=3), DRB (n=5); from three 
independent experiments].  
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4.1.2 ENT2 membrane localization 
 
Western blot analysis of ENT2 revealed protein localization similar to that of ENT1, with 
a pronounced protein band at 83 kDa (not shown in figure) and two other protein bands near 60 
kDa and 50 kDa, as seen in Figure 4.3A.  We found significant changes among treatment groups 
for the 60 kDa protein ENT2 protein (p<0.001), but not for the 50 kDa band (p>0.05) (Figure 4.3 
B, C) in membrane fractions.  The protein band near 83 kDa was not analyzed.  Comparing the 
treatment groups to the controls, we observed that DMAT (5 mol/L), TBB (10 mol/L) and DRB 
(100 mol/L) reduced the membrane localization of the 60 kDa ENT2 by 32 % (0.68507+/- 
0.08686; p<0.01), 56 % (0.43618 +/- 0.06179; p<0.001) and 53 % (0.46946 +/-0.09648; 
p<0.001), respectively (Figure 4.3B).  There was no significant change in the cytosolic 
localization of either the 50 kDa or 60 kDa protein band among the treatment groups, when 
compared to the control (Figure 4.4).   
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Figure 4.3. CK2 inhibition decreases ENT2 localization in membrane fractions.  Hippocampal slices were 
exposed to either control DMSO, DMAT (5 M), TBB (10 M) or DRB (100 M) for 1.5hr.  The membrane and 
cytosolic fractions of hippocampal homogenates were separated by centrifugation and used for Western Blot 
analysis.  A.  CK2 inhibition causes ENT2 to be reduced in membrane fractions.  Top.  Representative Western blots 
showing ENT2 bands near 50 kDa and 60 kDa.  Bottom.  GAPDH protein bands (~37 kDa) used to normalize ENT2 
signals.  B-C.  Quantitative representation of multiple Western blots showing inhibition of CK2 caused a significant 
reduction in ENT2 membrane localization (p<0.0001, one-way ANOVA).  Values for ENT2 (60 kDa) are means ± 
SEM from 8 independent blots from four experiments (n=8).  **p<0.01, ***p<0.001 vs. control.  ENT2 (50 kDa) 
signals from the different treatments [n=6 for all treatments] did not differ significantly (p=0.1957). 
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Figure 4.4.  CK2 inhibition does not alter cytosolic localization of ENT2.  Hippocampal slices were exposed to 
either control DMSO, DMAT (5 M), TBB (10 M) or DRB (100 M) for 1.5hr.  The membrane and cytosolic 
fractions of hippocampal homogenates were separated by centrifugation and used for Western Blot analysis.  A.  
Inhibition of CK2 does not cause internalization of ENT2 in cytosolic fractions.  Top. Representative Western blots 
showing ENT2 bands near 50 kDa and 60 kDa.  Bottom. GAPDH protein bands (~37 kDa) used to normalize ENT2 
signals.  B-C.  Quantitative representation of multiple Western blots showing inhibition of CK2 does not cause 
significant change (p>0.05) in the 60 kDa (p=0.9463) or 50 kDa (p=0.8655) ENT2 protein in cytosolic fractions.  
Values are means ± SEM [ENT2 60 kDa- DMSO (n=3), DMAT (n=3), TBB (n=2) and DRB (3); from three 
independent experiments] [ENT2 50 kDa- DMSO (n=7), DMAT (n=6), TBB (n=2), DRB (n=7); from five 
independent experiments].  
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4.1.3 ENT1 and ENT2 localization at the neuronal synapse 
 
Because ENT1 and ENT2 are localized in glial cells as well as neuronal cells, a clear 
disadvantage of using the hippocampal slice preparation and membrane and cytosolic 
fractionation was that the two cell types could not be separated.  Thus, a synaptosomal 
preparation was used to get a clearer understanding of what was happening at the nerve 
terminals, relative to the rest of the tissue.  
 To verify our synaptosome isolation procedure, protein samples were probed with 
synapsin 1a/b (Santa Cruz), a pre-synaptic marker that recognizes synaptic vesicle-associated 
phospho-proteins.  A strong protein signal was detected for synapsin at approximately 80 kDa 
(Figure 4.5), suggesting that our samples were enriched synaptosomes.  As with the membrane 
and cytosolic preparations, the ENT1 and ENT2 antibodies (Abcam) recognized protein bands at 
50 and 60 kDa, as shown in Figure 4.6A, C and Figure 4.7A, and at 83 kDa (not shown in figure) 
in the crude synaptosomal fractions.  However, unlike the hippocampal membrane fraction, there 
was no significant change in the localization of ENT1 or ENT2 among any of the CK2 treatment 
groups at the neuronal synapse, for both the 50 and 60 kDa protein bands, nor was there a 
significant change in ENT1 or ENT2 localization at the neuronal synapse with application of 
500nmol/L CPA (an adenosine analogue) for either 90 or 30 min, or 10 mol/L of the direct ENT 
inhibitor DPY, (Figure 4.6B,D and Figure 4.7B, C).   
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Figure 4.5. Synapsin Western blot.  Top. Representative Western blot showing synapsin band signals near 80 kDa 
in the synaptosomal fraction of hippocampal slices.  Bottom. GAPDH protein bands (~37 kDa) used to normalize 
synapsin signals. CPA, adenosine N
6
-cyclopentyladenosine (adenosine analogue); DPY, dipyridamole (ENT 
inhibitor).  
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Figure 4.6.  Localization of ENT1 in synaptosomal fractions following the inhibition of CK2 and ENTs.  
Hippocampal slices were exposed to either control DMSO, CPA (500nM), DPY (10 M), DMAT (5 M), or DRB 
(100 M) for 1.5hr (or 30 min for CPA). Hippocampal homogenates were separated into crude synaptosome 
fractions used for Western Blot analysis.  A, C.  Inhibition of CK2 or ENT, or application of CPA did not cause a 
significant change in ENT1 localization at the synapse.  Top. Representative Western blots showing ENT1 bands 
near 60 kDa and 50 kDa.  Bottom. GAPDH protein bands (~37 kDa) used to normalize ENT1 signals.  B, D. 
Quantitative representation of multiple Western blots showing that CPA or inhibition of CK2 or ENT did not 
significantly change ENT1 localization in the synaptosomal fraction. (p=0.8388, 60 kDa ENT1; p=0.9381, 50 kDa 
ENT1, one-way ANOVA).  Values are means ± SEM [ENT1 60 kDa- DMSO (n=6), CPA (90 min) (n=2), CPA (30 
min) (n=4), DPY (n=6), DMAT (n=6), and DRB (n=6)] [ENT1 50 kDa- DMSO (n=8), CPA (90 min) (n=4), CPA 
(30 min) (n=4), DPY (n=8), DMAT (n=8), and DRB (n=8)]. CPA, adenosine N
6
-cyclopentyladenosine (adenosine 
analogue); DPY, dipyridamole (ENT inhibitor). 
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Figure 4.7.  Localization of ENT2 in synaptosomal fractions following the inhibition of CK2 and ENTs.  
Hippocampal slices were exposed to either control DMSO, CPA (500nM), DPY (10 M), DMAT (5 M), or DRB 
(100 M) for 1.5hr (or 30 min for CPA).  Hippocampal homogenates were separated into synaptosomal fractions and 
used for Western Blot analysis.  A.  Inhibition of CK2 or ENT, or the application of CPA did not cause a significant 
change in ENT2 localization in synaptosomal fractions.  Top. Representative Western blots showing ENT2 bands 
near 60 kDa and 50 kDa.  Bottom. GAPDH protein bands (~37 kDa) used to normalize ENT2 signals.  B-C. 
Quantitative representation of multiple Western blots showing that the application of CPA or the inhibition of CK2 
or ENT did not significantly change ENT2 localization in the synaptosomal fraction. (p=0.0879, 60kDa ENT2; 
p=0.0574, 50 kDa ENT2, one-way ANOVA).  Values are means ± SEM [ENT2 60 kDa- DMSO (n=2), CPA (90 
min) (n=2), DPY (n=2), and DMAT (n=2)] [ENT2 50 kDa- DMSO (n=10), CPA (90 min) (n=7), CPA (30 min) 
(n=3), DPY (n=10), DMAT (n=9), and DRB (n=6)]. 
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4.2 ENTs are physically associated with proteins involved in synaptic transmission 
  
Immunoprecipitation is the technique that is used to isolate and concentrate a known 
protein of interest.  With co-immunoprecipitation, it is possible to identify unknown members of 
a larger protein complex by targeting a known protein with a specific antibody and thus isolating 
it as well as all other proteins that are physically associated with it. Here we used co-
immunoprecipitation to identify other proteins that may be physically associated with ENT1 and 
ENT2 to gain more knowledge of ENT signaling in the rat hippocampus.    
Previous reports show that ENT inhibition raises extracellular adenosine tone and causes 
synaptic depression (Dunwiddie and Masino, 2001), however it is not yet known whether 
changes in glutamate receptors accompany this effect of ENT inhibition.  Here, 
immunoprecipitation experiments were performed to determine whether the GluR1 or GluR2 
AMPA receptor subunits exist in the same signaling complex as ENT1 or ENT2 in the rat 
hippocampus.  Immunoprecipitation of whole cell hippocampal lysates with rabbit anti-ENT1 or 
rabbit anti-ENT2 antibodies (Abcam) and subsequent immunoblotting with polyclonal rabbit 
anti-GluR1 (Abcam) revealed the presence of GluR1 proteins in both ENT1 and ENT2 
immunoprecipitates (Figure 4.8, Top, lane 2 and 3).  These protein bands were not present when 
the immunoprecipitating antibody was omitted (Figure 4.8, Top, lane 1).  Subsequently, the 
immunoprecipitated ENT1 and ENT2 proteins were immunoblotted with monoclonal mouse 
anti-GluR2 (Millipore) and the presence of GluR2 proteins was detected in both ENT1 and 
ENT2 immunoprecipitates (Figure 4.8, Bottom, lane 2 and 3).  Again, the protein bands were not 
present when the immunoprecipitating antibody was omitted (Figure 4.8, Bottom, lane 1), 
serving as a negative control.  This data suggests that both GluR1 and GluR2 are physically 
associated with ENT1 and ENT2 and that there is an intimate relationship between adenosine 
signaling and synaptic transmission in the rat hippocampus. 
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Figure 4.8. Adenosine transporters physically associate with AMPA receptor subunits.  Immunoprecipitation 
(IP) data showing that ENT1 and ENT2 proteins are physically associated with GluR1 and GluR2 AMPA receptor 
subunits. Top. Protein A/G-PLUS- Agarose (negative control) and whole cell lysates were used in IP.  Whole cell 
lysates immunoprecipitated with rabbit anti-ENT1 (Abcam), rabbit anti-ENT2 (Abcam), and whole cell lysates 
(positive control).  GluR1 protein bands are recognized at ~106 kDa (Abcam) and GluR2 protein bands exist near 96 
kDa (Millipore). 
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4.3 Inhibition of protein kinase CK2 alters AMPA receptor localization 
 
Western blot analysis was performed to evaluate the effects of CK2 inhibition on the 
surface localization of the AMPA receptor subunits, GluR1 and GluR2 (Figure 4.9, 4.10).  Since 
we have found a novel interaction between ENTs and GluR1 and GluR2-containing AMPA 
receptors (see above, Figure 4.8), we next tested whether the inhibition of CK2 function with 
DMAT, TBB and DRB also altered the membrane localization of GluR1 or GluR2 in native rat 
hippocampal tissue slices.  We found, from five independent experiments, that inhibition of CK2 
activity caused a significant reduction in the amount of GluR1 present at the plasma membrane 
(p<0.0001).  Compared to control groups, DMAT (5 mol/L), TBB (10 mol/L) and DRB 
(100 mol/L) reduced the membrane localization of GluR1 by 29% (0.71255 +/- 0.07724; 
p<0.001), 35% (0.64942 +/- 0.07265; p<0.001) and 35% (0.64824 +/-0.06258; p<0.001), 
respectively (Figure 4.9B).  However, it was apparent, from the densitometry of two reproducible 
blots showing the cytosolic expression of GluR1, that there was no change in the GluR1 
cytosolic localization after CK2 inhibition (Figure 4.9C, D). 
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Figure 4.9.  Inhibition of CK2 causes a reduction in membrane localization of GluR1.  Hippocampal slices were 
exposed to either control DMSO, DMAT (5 M), TBB (10 M) or DRB (100 M) for 1.5hr.  The membrane and 
cytosolic fractions of hippocampal homogenates were separated by centrifugation and used for Western Blot 
analysis.   A.  Top.  Representative Western blots showing that GluR1 band signals in the membrane fraction, near 
106 kDa, are decreased by CK2 inhibitors.  Bottom.  GAPDH protein bands (~37 kDa) are used to normalize GluR1 
signals.  B. Quantitative representation of multiple Western blots showing inhibition of CK2 caused GluR1 
internalization in membrane fraction (p<0.0001, one-way ANOVA).  Values are means ± SEM [DMSO (n=12), 
DMAT (n=10), TBB (n=11) and DRB (n=12); from five independent experiments].  **p<0.001 vs. control.  C.  
Representative Western blots showing that there is no change in the GluR1 band signals in the cytosolic fraction by 
CK2 inhibitors.  D. Quantitative representation of two Western blots showing that there was no apparent change in 
the cytosolic localization of GluR1 by CK2 inhibition or direct ENT inhibition [n=2 for all treatments].  
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Similarly, when compared to the control groups, the amount of GluR2 present at the 
plasma membrane after treatment with DMAT (5 mol/L), TBB (10 mol/L) and DRB ( mol/L) 
was reduced by 41% (0.59286 +/- 0.13991; p<0.01), 56% (0.4387 +/- 0.06655; p<0.001) and 
40% (0.60376 +/-0.06737; p<0.01), respectively (Figure 4.10B).  Values are from four 
independent experiments with an overall significance of p<0.0001.  Alternately, there was no 
significant change (p>0.05) in the cytosolic localization of GluR2, compared to the DMSO 
control (Figure 4.10D). 
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Figure 4.10.  Inhibition of CK2 causes a reduction in membrane localization of GluR2 .  Hippocampal slices 
were exposed to either control DMSO, DMAT (5 M), TBB (10 M) or DRB (100 M) for 1.5hr.  The membrane and 
cytosolic fractions of hippocampal homogenates were separated by centrifugation and used for Western Blot 
analysis.  A.  Top. Representative Western blots showing that GluR2 band signals near 96 kDa are decreased by 
CK2 inhibitors.  Bottom. GAPDH protein bands (~37 kDa) are used to normalize GluR2 signals.  B. Quantitative 
representation of multiple Western blots showing inhibition of CK2 caused a reduction of GluR2 in the membrane 
fraction (p<0.0001, one-way ANOVA).  Values are means ± SEM [DMSO (n=13), DMAT (n=12), TBB (n=12) and 
DRB (n=12); from four independent experiments].  **p<0.01 and ***p<0.001 vs. control.  C.  Top.  Representative 
Western blots showing that there is no change in the GluR2 band signals in the cytosolic fraction by CK2 inhibitors.  
Bottom.  GAPDH protein bands (~37 kDa) are used to normalize GluR2 signals.  D.  Quantitative representation of 
multiple Western blots showing that there was no significant change (p=0.9955, one-way ANOVA) in the cytosolic 
localization of GluR2 by CK2 inhibition [DMSO (n=8), DMAT (n=6), TBB (n=5), DRB (n=8); from four 
independent experiments].  
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Together, these results suggest that GluR1 and GluR2-containing AMPA receptor 
trafficking from the membrane coincides with a similar pattern of ENT trafficking from the 
membrane after CK2 inhibition.  However, similar to what we found with ENT1 and ENT2, 
densitometry analysis of GluR1 and GluR2 at the neuronal synapse revealed that there was no 
significant change (p>0.05) in the localization of either GluR1 or GluR2 in this region of the cell 
after incubation with CK2 inhibitors (DMAT and DRB for GluR2) or the direct ENT inhibitor 
DPY, or the adenosine analogue CPA (Figures 4.11, 4.12).  This suggests that the regulation of 
GluR1 and GluR2 localization by CK2 inhibition may be specific to certain regions of the nerve 
cell. 
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Figure 4.11.  The effect of CPA and ENT inhibition on the localization of GluR1 in synaptosomal fractions.  
Hippocampal slices were exposed to either control DMSO, CPA (500nM; 90, 45 0r 30 min), DPY (10 M; 1.5hr). 
Hippocampal homogenates were separated into synaptosomal fractions and used for Western Blot analysis.  A, C.  
Inhibition of ENT did not cause a significant change in GluR1 localization in synaptosomal fractions. Representative 
Western blots showing GluR1 bands near 106 kDa. GAPDH protein bands (~37 kDa) used to normalize GluR1 
signals.  B. Quantitative representation of multiple Western blots showing inhibition of ENT did not significantly 
change GluR1 localization in the synaptosomal fraction. (p=0.7765, one-way ANOVA).  Values are means ± SEM 
[DMSO (n=11), CPA (90 min) (n=8), CPA (45 min) (n=6), CPA (30 min) (n=10) and DPY (n=5)]. 
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Figure 4.12.  Application of the adenosine analogue CPA, ENT inhibition, or CK2 inhibition does not 
significantly change the localization of GluR2 in synaptosomal fractions.  Hippocampal slices were exposed to 
either control DMSO, CPA (500nM), DPY (10 M), DMAT (5 M), or DRB (100 M) for 1.5hr (or 90, 45 or 30 min 
for CPA). Hippocampal homogenates were separated into synaptosomal fractions and used for Western Blot 
analysis.  A, C.  Application of CPA of the inhibition of CK2 or ENT did not cause a significant change in GluR2 
localization in synaptosomal fractions. Representative Western blots showing GluR2 bands near 96 kDa. GAPDH 
protein bands (~37 kDa) used to normalize GluR2 signals.  B. Quantitative representation of multiple Western blots 
showing CPa inhibition of CK2 or ENT did not significantly change GluR2 localization in the synaptosomal 
fraction. (p=0.2919, one-way ANOVA).  Values are means ± SEM [DMSO (n=26), CPA (90 min) (n=17), CPA (45 
min) (n=6), CPA (30 min) (n=3), DPY (n=17), DMAT (n=25), and DRB (n=13)]. 
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4.4 Effect of temperature on ENT and AMPA receptor localization  
 
It is known that the basal concentration of extracellular adenosine in rat hippocampal 
slices that are maintained at 21 C is approximately twice that at 32 C, thus it is apparent that the 
extracellular concentrations of adenosine in the brain are sensitive to temperature (Dunwiddie 
and Diao, 2000).  It is suggested that this is due to a reduction in the function of ENT2, as ENT1 
is less sensitive to temperature change (Dunwiddie and Diao, 2000).  We therefore wanted to 
determine if the membrane localization of ENT1 or ENT2 was more or less sensitive to direct 
inhibition with varying temperatures.   
As shown in Figure 4.13 and 4.14A, we found that there was a significant increase in the 
localization of the 60 kDa ENT1 protein in the membrane fraction of hippocampal tissue slices 
that were incubated, at room temperature (~21 C), with both 10nM (1.37321 +/- 0.1249; 
p<0.001) and 100nM (1.47084 +/- 0.0691; p<0.001) of the ENT1-specific inhibitor, NBTI, when 
compared to control DMSO.  Additionally, we found that the membrane localization of the 50 
kDa ENT1 was significantly enhanced after treatment with NBTI (10nM) (1.35987 +/- 0.17197) 
compared to the control (p<0.01), however there was no significant effect of NBTI (100nM) 
(1.08771 +/- 0.03414) compared to the control (Figure 4.14C), at room temperature. 
We found that there was no significant change (p>0.05) in the membrane expression of 
the 50 or 60 kDa ENT1 protein in hippocampal slices that were incubated at 35 C (Figure 
4.14B,D).  There was also no significant difference (p>0.05) in the localization of either the 50 or 
60 kDa ENT1 protein in the cytosolic fraction of the cell at either RT or 35 C (Figure 4.15 and 
Figure 4.16). 
 
 
  
 
 
 
 
 
 
 
 
 
 
 51 
 
 
     
 
Figure 4.13. ENT1 membrane localization at RT and 35°C.  Top. Representative Western blots showing that 
ENT1 band signals near 50 and 60 kDa are enhanced by the ENT1 inhibitor NBTI at RT in the membrane fraction of 
hippocampal slices. Bottom. GAPDH protein bands (~37 kDa) are used to normalize ENT1 signals. 
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Figure 4.14. ENT1 inhibition causes an up-regulation of ENT1 surface localization at RT.  Hippocampal slices 
were exposed to either control DMSO, NBTI (100nM) or NBTI (10nM) for 1.5hr at either RT or 35°C. The 
membrane and cytosolic fractions of hippocampal homogenates were separated by centrifugation and used for 
Western Blot analysis. A, C. Quantitative representation of multiple Western blots showing inhibition of ENT1 with 
NBTI enhanced the surface localization of the 50 and 60 kDa ENT1 protein at room temperature (p<0.0001, one-
way ANOVA).  Values are means ± SEM [ENT1 60 kDa- DMSO (n=12), NBTI-100nM (n=4) and NBTI-10nM 
(n=4)] [ENT1 50 kDa- DMSO (n=16), NBTI-100nM (n=4), NBTI-10nM (n=3)]. **p<0.01, ***p<0.001 vs. control. 
B, D. Quantitative representation of multiple Western blots showing inhibition of ENT1 did not cause a significant 
change in the localization of the 50 (p=0.2835, on-way ANOVA) or 60 kDa (p=0.3060, one-way ANOVA) ENT1 
protein at 35°C in membrane fraction. Values are means ± SEM [ENT1 60 kDa- DMSO (n=4), NBTI-100nM (n=4), 
and NBTI-10nM (n=4)] [ENT1 50 kDa- DMSO (n=6), NBTI-100nM (n=3), and NBTI-10nM (n=2)]. 
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Figure 4.15. Cytosolic localization of ENT1 at RT and 35°C.  Top. Representative Western blots showing that, in 
the cytosolic fraction of cells from hippocampal tissue slices, ENT1 band signals near 50 and 60 kDa do not 
significantly change after treatment with ENT inhibitors NBTI or DPY at RT or 35°C. Bottom. GAPDH protein 
bands (~37 kDa) are used to normalize ENT1 signals. 
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Figure 4.16. ENT inhibition does not affect the cytosolic localization of ENT1 at RT or 35°C.  Hippocampal 
slices were exposed to either control DMSO, NBTI (100nM), NBTI (10nM) or DPY (10 M) for 1.5hr at either RT 
or 35°C. The membrane and cytosolic fractions of hippocampal homogenates were separated by centrifugation and 
used for Western Blot analysis.  A, C. Quantitative representation of multiple Western blots showing inhibition of 
ENTs does not significantly affect the localization of the 50 and 60 kDa ENT1 protein at room temperature 
(p=0.5237; p=0.3487, respectively, one-way ANOVA).  Values are means ± SEM [ENT1 60 kDa- DMSO (n=10), 
NBTI-100nM (n=5) and DPY (n=5)] [ENT1 50 kDa- DMSO (n=7), NBTI-100nM (n=2) and DPY (n=5)]. B, D. 
Quantitative representation of multiple Western blots showing inhibition of ENT1 did not cause a significant change 
in the localization of the 50 or 60 kDa ENT1 protein at 35°C in membrane fraction (p=0.5870; p=0.6722, 
respectively, one-way ANOVA). Values are means ± SEM [ENT1 60 kDa- DMSO (n=5), NBTI-100nM (n=5), and 
NBTI-10nM (n=2)] [ENT1 50 kDa- DMSO (n=2) and NBTI-100nM (n=2)].  
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In this set of experiments, only the ENT2 protein at 50 kDa was detectible, perhaps due to 
an insufficient exposure time during the ECL (Figure 4.17A,C).  Nevertheless, analogous to what 
was seen in the localization of the 50 kDa ENT2 protein with CK2 inhibition, we found that, 
compared to the control, NBTI (10nM), NBTI (100nM), and DPY (10 M) did not cause any 
significant changes (p>0.05) in the membrane localization of ENT2 at RT or 35 C (Figure 
4.17B, D).  Again, there were no significant changes (p>0.05) in the localization of ENT2 in the 
cytosolic fraction at RT, or at 35 C in the cytosolic fractions (Figure 4.18).  
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Figure 4.17. Membrane localization of ENT2 in the hippocampus is not significantly affected by ENT 
inhibition at RT or 35°C. Hippocampal slices were exposed to either control DMSO, NBTI (100nM), NBTI 
(10nM) or DPY (10 M) for 1.5hr at either RT or 35°C. The membrane and cytosolic fractions of hippocampal 
homogenates were separated by centrifugation and used for Western Blot analysis. A, C. Representative Western 
blots showing that ENT2 band signals at 50 kDa, in the hippocampal membrane fraction, are not changed by ENT 
inhibitors at RT or 35°C. GAPDH protein bands (~37 kDa) are used to normalize GluR1 signals.  B, D. Quantitative 
representation of multiple Western blots showing inhibition of ENTs did not significantly affect surface localization 
of the 50 kDa ENT2 protein at room temperature (p=0.0618, one-way ANOVA; B) or 35°C (p=0.0897, one-way 
ANOVA; D).  Values are means ± SEM [ENT2 50 kDa RT- DMSO (n=16), NBTI-100nM (n=5), NBTI-10nM (n=4) 
and DPY (n=12)] [ENT2 50 kDa 35°C- DMSO (n=11), NBTI-100nM (n=5), NBTI-10nM (n=4), DPY (n=6)].  
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Figure 4.18. Cytosolic localization of ENT2 in the hippocampus is not significantly affected by ENT inhibition 
at RT or 35°C. Hippocampal slices were exposed to either control DMSO, NBTI (100nM), NBTI (10nM) or DPY 
(10 M) for 1.5hr at either RT or 35°C. The membrane and cytosolic fractions of hippocampal homogenates were 
separated by centrifugation and used for Western Blot analysis. A, C. Representative Western blots showing that 
ENT2 band signals at 50 kDa, in the hippocampal cytosolic fraction, are not changed by ENT inhibitors at RT or 
35°C. GAPDH protein bands (~37 kDa) are used to normalize GluR1 signals.  B, D. Quantitative representation of 
multiple Western blots showing inhibition of ENTs did not significantly affect cytosolic localization of the 50 kDa 
ENT2 protein at room temperature (p=0.2644, one-way ANOVA; B) or 35°C (p=0.3050, one-way ANOVA; D).  
Values are means ± SEM [ENT2 50 kDa RT- DMSO (n=12), NBTI-100nM (n=4), NBTI-10nM (n=2), DPY (n=10)] 
[ENT2 50 kDa 35°C- DMSO (n=5), NBTI-100nM (n=4), NBTI-10nM (n=2), DPY (n=4)].  
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In the membrane fraction of the cell, direct ENT inhibition with NBTI at RT showed a 
trend toward the up-regulation of GluR1 and GluR2 surface localization, whereas DPY showed a 
trend the down-regulation of GluR1 and GluR2 surface localization (Figures 4.19A, C and 
4.21A, C); however, this change was not significant (p>0.05) compared to the control (Figure 
4.19B, 4.21B).  Additionally, there were no significant changes (p>0.05) among the treatment 
groups for GluR1 and GluR2 cytosolic fractions at room temperature, and there were no 
significant changes (p>0.05) in the localization of GluR1 or GluR2 at 35 C (Figures 4.19-4.22).  
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Figure 4.19.  Inhibition of ENTs does not cause a reduction of GluR1 in membrane fractions at RT or 35°C.  
Hippocampal slices were exposed to control DMSO aCSF, NBTI (100nM), NBTI (10nM) or DPY (10 M) for 1.5hr 
at either RT or 35°C.  The membrane and cytosolic fractions of hippocampal homogenates were separated by 
centrifugation and the membrane fraction was used for Western Blot analysis.  A, C. Representative Western blots 
showing that GluR1 band signals at RT and 35°C in the membrane fraction, near 106 kDa, are not changed by ENT 
inhibitors. GAPDH protein bands (~37 kDa) are used to normalize GluR1 signals. B. Quantitative representation of 
multiple Western blots showing inhibition of ENTs did not cause a significant change in GluR1 surface localization 
at RT (p=0.7358, one-way ANOVA).  Values are means ± SEM [DMSO (n=21), NBTI-100nM (n=5), NBTI-10nM 
(n=5) and DPY (n=17)]. D. Quantitative representation of multiple Western blots showing that there was no 
significant change in the membrane localization of GluR1 by ENT inhibition at 35°C. (p=0.1483, one-way 
ANOVA).  Values are means ± SEM [DMSO (n=8), NBTI-100nM (n=5), NBTI-10nM (n=5) and DPY (n=4)]. 
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Figure 4.20.  Inhibition of ENTs does not change GluR1 localization in cytosolic fractions at RT or 35°C.  
Hippocampal slices were exposed to either control DMSO, NBTI (100nM), NBTI (10nM) or DPY (10 M) for 1.5hr 
at either RT or 35°C.  The membrane and cytosolic fractions of hippocampal homogenates were separated by 
centrifugation and the membrane fraction was used for Western Blot analysis.   A, C. Representative Western blots 
showing that GluR1 band signals at RT and 35°C in the cytosolic fraction, near 106 kDa, are not changed by ENT 
inhibitors. GAPDH protein bands (~37 kDa) are used to normalize GluR1 signals. B.  Quantitative representation of 
multiple Western blots showing inhibition of ENTs did not cause a significant change in GluR1 cytosolic 
localization at RT (p=0.7977, one-way ANOVA).  Values are means ± SEM [DMSO (n=8), NBTI-100nM (n=3), 
NBTI-10nM (n=2) and DPY (n=4)].  D. Quantitative representation of multiple Western blots showing that there 
was no significant change in the cytosolic localization of GluR1 by ENT inhibition at 35°C. (p=0.6154, one-way 
ANOVA).  Values are means ± SEM [DMSO (n=6), NBTI-100nM (n=3), NBTI-10nM (n=2) and DPY (n=5)]. 
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Figure 4.21.  Inhibition of ENTs does not cause a reduction in GluR2 localization in membrane fractions at 
RT or 35°C.  Hippocampal slices were exposed to either control DMSO, NBTI (100nM), NBTI (10nM) or DPY 
(10 M) for 1.5hr at either RT or 35°C.  The membrane and cytosolic fractions of hippocampal homogenates were 
separated by centrifugation and the membrane fraction was used for Western Blot analysis.   A, C.  Representative 
Western blots showing that GluR2 band signals at RT and 35°C in the membrane fraction, near 96 kDa, are not 
changed by ENT inhibitors. GAPDH protein bands (~37 kDa) are used to normalize GluR2 signals. B.  Quantitative 
representation of multiple Western blots showing inhibition of ENTs did not cause a significant change in GluR2 
surface localization at RT (p=0.0518, one-way ANOVA).  Values are means ± SEM [DMSO (n=23), NBTI-100nM 
(n=6), NBTI-10nM (n=7) and DPY (n=16)]. D. Quantitative representation of multiple Western blots showing that 
there was no significant change in the membrane localization of GluR2 by ENT inhibition at 35°C. (p=0.7436, one-
way ANOVA).  Values are means ± SEM [DMSO (n=10), NBTI-100nM (n=6), NBTI-10nM (n=7) and DPY (n=3)]. 
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Figure 4.22.  Inhibition of ENTs does not change GluR2 localization in cytosolic fractions at RT or 35°C.  
Hippocampal slices were exposed to either control DMSO, NBTI (100nM), NBTI (10nM) or DPY (10 M) for 1.5hr 
at either RT or 35°C.  The membrane and cytosolic fractions of hippocampal homogenates were separated by 
centrifugation and the membrane fraction was used for Western Blot analysis.   A, C. Representative Western blots 
showing that GluR2 band signals at RT and 35°C in the cytosolic fraction, near 96 kDa, are not changed by ENT 
inhibitors. GAPDH protein bands (~37 kDa) are used to normalize GluR2 signals. B.  Quantitative representation of 
multiple Western blots showing inhibition of ENTs did not cause a significant change in GluR2 cytosolic 
localization at RT (p=0.6847, one-way ANOVA).  Values are means ± SEM [DMSO (n=12), NBTI-100nM (n=2), 
NBTI-10nM (n=3) and DPY (n=8)].  D.  Quantitative representation of multiple Western blots showing that there 
was no significant change in the cytosolic localization of GluR2 by ENT inhibition at 35°C. (p=0.1060, one-way 
ANOVA).  Values are means ± SEM [DMSO (n=4), NBTI-100nM (n=2), NBTI-10nM (n=3) and DPY (n=3)]. 
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CHAPTER 5 
 
GENERAL DISCUSSION 
  
Equilibrative nucleoside transporters ENT1 and ENT2 are expressed ubiquitously in 
plasma membranes of mammalian cells, and are distributed throughout the central nervous 
system, including the hippocampus (Jennings et al., 2001).  Little is known about the how the 
localization of these transporters is regulated but a variety of reports suggest that ENTs can be 
modified by kinase-dependent pathways (Coe et al., 1996; Coe et al., 2002; Kong et al., 2004; 
Bone et al., 2007).  ENT1 and ENT2 have a large intracellular loop joining transmembrane 
domains 6 and 7, which contains sites for phosphorylation by CK2 (Kiss et al., 2000; Handa et 
al., 2001; Stolk et al., 2005).  Thus, the presence of these phosphorylation sites suggests that the 
transporter activity and/or membrane localization of ENTs could be subject to modulation by 
CK2.   
 
5.1 Membrane localization of ENTs 
 
ENT1 and ENT2 are expressed on the plasma membrane (Alanko et al., 2006) of 
neuronal and non-neuronal cells (Anderson et al., 1999a; Anderson et al., 1999b; Parkinson et al., 
2005) and are localized in regions of the brain known to contain adenosine receptors (Anderson 
et al., 1999a; Anderson et al., 1999b; Jennings et al., 2001), emphasizing the importance of these 
transporters in the regulation of adenosine tone.  Here we confirm the presence of ENT1 and 
ENT2 in membrane fraction of cells prepared from rat hippocampal tissue, and show that these 
transporter proteins are located at 50 and 60 kDa, and that there is also a high concentration of 
these proteins at 83 kDa, previously described to be ENT protein dimers (Reyes et al.).  
Hippocampal membrane fractions were prepared in this study to determine whether the 
membrane localization of these transporters could be altered by CK2 inhibition.  Here, we have 
shown that incubation of hippocampal tissue slices with CK2 inhibitors resulted in a significant 
decrease in ENT1 (33-43%; p<0.01) and ENT2 (32-56%; p<0.001) protein density in 
hippocampal membrane fractions, inferred as a decrease in membrane localization of the 60 kDa 
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transporter protein.  This data implies that ENT1 and ENT2 protein localization in hippocampal 
tissue may normally be regulated by CK2 activity.   
It was not confirmed whether CK2 inhibition prevented the phosphorylation of ENT1 and 
ENT2 at CK2 consensus sites in this study, however the findings presented here are in agreement 
with those of Bone et al. 2007, who found that inhibition of CK2 activity with TBB produced a 
reduction in the number of functional ENT1 proteins at the level of the plasma membrane.  
Deletion of Ser-254 from mouse ENT1 also renders ENT1 levels insensitive to TBB-mediated 
inhibition of CK2 (Bone et al., 2007).  Together, this evidence strongly implies that Ser-254 is 
phosphorylated by CK2 in ENT1.  However, Stolk et al. 2005 suggests that the inhibition of CK2 
activity has a dual effect on ENT1, as they observed transient inhibition of ENT1 transcription 
followed by a delayed post-transcriptional increase in the number of transporters functioning at 
the plasma membrane, after the induction of the catalytically inactive CK  in osteosarcoma 
cells.  They also observed a reduction in the plasma membrane localization of ENT2, which was 
parallel to a reduction in the level of mENT2 mRNA (Stolk et al., 2005).  Here we found no 
significant change (p>0.05) in the cytosolic localization of ENT1 and ENT2 (Figures 4, 6), 
however, because the relative concentration of these transporters in the membrane and cytosolic 
fractions were not directly compared, it is difficult to determine whether the ENTs were 
undergoing trafficking between the plasma membrane and intracellular stores, as seen with 
glucose transporters (Baldwin et al., 1995), or whether they were being rapidly endocytosed and 
degraded.  Thus, the mechanism by which CK2-mediated phosphorylation regulates the 
membrane localization of ENT1 and ENT2 requires further investigation, and it may be 
beneficial to employ more precise techniques, such as a cell surface biotinylation assay (Gallyas 
et al., 2003), for future study to confirm the membrane trafficking of these proteins.  
  The concentration of ENT proteins detected near 50 kDa was greater than that detected 
at 60 kDa, however inhibition of CK2 function did not cause significant changes in the 
concentration of these proteins; only the 60 kDa proteins were significantly altered by CK2 
inhibition.  Although it is not recognized in rat or human tissue, a splice variant of ENT1 has 
been identified in murine tissue (Kiss et al., 2000; Handa et al., 2001).  The shorter of the two 
splice variants, mENT1a, has greater expression in brain tissue than the larger variant, mENT1b 
(Bone et al., 2007).  It has also been shown that the number of mENT1b transporters operating at 
the level of the plasma membrane are down regulated by CK2 inhibition, while mENT1a are not 
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(Bone et al., 2007).  It is possible that there also exists a rat ENT1 splice variant that has not yet 
been identified.  The presence of a rat splice variant may help to account for the lack of 
susceptibility to regulation by CK2-mediated phosphorylation observed in the 50 kDa proteins 
relative to that of the 60 kDa proteins; however this is purely hypothetical and needs further 
experimental confirmation.  Alternately, it is likely that the 50 kDa proteins represent ENT 
proteins that have undergone less post-translational modification compared to the 60 kDa 
proteins, for example, less N-linked glycosylation.  Although ENT proteins have been detected at 
various molecular weights, it is apparent from the number of non-specific protein bands in the 
ENT1 and ENT2 Western blots that the specificity of the ENT antibodies is a caveat of this 
study.  While an antigenic peptide for the ENT antibodies was used as an attempt to address this 
issue, the results were inconclusive as the antibodies and peptides used were extremely sensitive 
to the blotting procedure, and optimization of the signal was not possible.   
To ensure that the effect of CK2 inhibition on ENT localization was not due to the 
activity of other intracellular proteins that might modify the localization and/or function of 
ENTs, a variety of CK2 inhibitors were used, at concentrations that have been shown by a 
number of other groups to selectively inhibit CK2 (Lieberman and Mody, 1999; Sarno et al., 
2001; Pinna, 2002; Pagano et al., 2004).  Each of the CK2 inhibitors used in this thesis are 
derivatives of the nucleoside analogue 5,6-dichloro-1-( -D-ribofuranosyl) benzimidazole (DRB).  
DRB has a Ki value of 23 M (Cozza et al.), and works by occupying the hydrophobic pocket 
adjacent to the ATP/GTP binding site in CK2 and competitively inhibits the binding of these 
phosphate donors (Cozza et al.; Sarno et al., 2001; Sarno et al., 2002; Sarno et al., 2005; 
Mazzorana et al., 2008).  DRB is somewhat of a dirty drug, as it is known to inhibit 
topoisomerase, cellular and viral RNA and result in relatively high cytotoxicity, however, the 
structure of this molecule has been progressively optimized and allowed for the development of 
derivatives that better interact with the ATP binding pocket, including both TBB and DMAT 
with Ki values of 0.40 and 0.04 M, respectively (Cozza et al.; Sarno et al., 2005).  Other protein 
kinases generally inhibited by CK2 ligands include PIM1, 2, 3, DYRK1a, 2, 3 and in some cases 
GSK3  and CDK2 (Cozza et al.).  However, when tested against a panel of 32 kinases other than 
CK2, DMAT and TBB affected only DYRK1a, with similar efficacy (Sarno et al., 2005).  
Furthermore, all of the CK2 inhibitors produced similar effects, giving indication that CK2 was 
selectively inhibited.  However, it cannot be guaranteed that CK2 inhibition did not change the 
 66 
activity of its other substrates that are known to modify ENT function and/or localization (Mead 
et al., 2003; Soler et al., 2003; Castelli et al., 2004; Sperlagh et al., 2004).  For instance, PKC is a 
known substrate for CK2 (Blanquet, 2000), and has been shown to modify the activity and 
expression of ENTs under some circumstances (Chaudary et al., 2004).   
Here we have confirmed that the membrane localization of ENT1 and ENT2 in the rat 
hippocampus is sensitive to changes in CK2 activity, such that CK2 inhibition causes a reduction 
in the concentration ENT1 and ENT2 in the membrane fraction.  Although the exact mechanism 
for these changes is unknown, it is evident that these changes in ENT localization may 
potentially alter the level of extracellular adenosine, thus altering adenosinergic signaling, and 
possibly the susceptibility of hippocampal cells to excitotoxicity during ischemic events.  
 
5.2 ENT localization at neuronal synapses 
  
Several groups have described the localization of ENT1 and ENT2 mRNA and protein in 
neurons and astrocytes (Anderson et al., 1999a; Anderson et al., 1999b; Parkinson et al., 2005).  
Additionally, CK2 activity is associated with synaptosomes (Girault et al., 1990), indicating that 
CK2 is present at substantial levels in nerve terminals (Blanquet, 2000).  To address the issue of 
having a mixture of neuronal and non-neuronal cells in our hippocampal lysate, synaptosomes 
were prepared in an attempt to separate the effect of CK2 inhibition in these different cell types.  
The data presented in this study indicates there was no significant (p>0.05) change in the 
localization of ENT1 or ENT2 in neuronal synapses after treatment with CK2 inhibitors (Figures 
4.6 and 4.7).  These findings differ from that observed in the membrane fraction of the cells 
prepared from hippocampal slices (Figures 4.1 and 4.3).  While the activity of CK2 in the brain is 
predominantly neuronal, it is also associated with glia (Girault et al., 1990; Parkinson et al., 
2005).  It is therefore possible that the overall reduction in ENT1 and ENT2 surface localization 
observed in the membrane fraction of the hippocampal lysates may be attributed to changes in 
ENT1 and ENT2 at extra-synaptic locations and in non-neuronal tissue.  Treatment with the 
adenosine analogue CPA or the direct ENT inhibitor DPY, which were used to simulate an 
increase in extracellular adenosine tone, also failed to cause any significant change (p>0.05) in 
the localization of ENT1 or ENT2 in the synaptosomal preparations.  However, ENT proteins 
have been identified in cortical synaptosomes, where adenosine transport is reduced in the 
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presence of DPY (Parkinson et al., 2009), yet this does not necessarily mean a reduction in 
localization at the synapse.  Another, and perhaps more effective, means to separate the glial cell 
contribution in our cell lysates would have been to use cultured hippocampal neurons and glia 
paired with immunocytochemistry to localized these receptors in each cell type.  While this 
technique was attempted, it still needs to be optimized in order to obtain reliable results.    
 
5.3 ENTs are physically associated with proteins involved in synaptic transmission 
 
There have been a few studies where the distribution of ENT1 and ENT2 mRNA or 
protein has been observed in regions of the rat and human brain that are also known to contain 
adenosine receptors (Anderson et al., 1999a; Anderson et al., 1999b; Jennings et al., 2001).  
Recently, our research group has found evidence that A1 adenosine receptors are physically 
associated with GluR2 AMPA receptors (Z. Chen, unpublished data), and here, via 
immunoprecipitation, we show that ENT1 and ENT2 are physically associated with the 
GluR1and GluR2 AMPA receptor subunits in whole cell hippocampal lysates (Figure 4.8).  
Together, this evidence suggests that these molecules might function together in a larger 
molecular complex, linking the regulation of adenosine signaling and AMPA receptor subunit 
redistribution. The direct signaling mechanism linking these molecules is not known; however, 
mitogen activated protein kinases (MAPKs) may be a key player in this proposed signaling 
complex.  Two subfamilies of MAPKs, p38 MAPK and c-Jun N-terminal kinase (JNK), have 
been shown to be an important link between adenosine A1 receptor activation and the inhibition 
of synaptic transmission pre-synaptically (Brust et al., 2006; Brust et al., 2007).  A role for p38 
MAPK and JNK has been implicated in the redistribution of GluR1 and GluR2 receptors 
(Boudreau et al., 2007).  Additionally, a link between nucleoside transport activity and the 
MAPK pathway has been proposed (Sperlagh et al., 2004), and CK2 has been reported to modify 
MAPK signaling cascades via interaction with both protein phosphatase 2A and MAPK 
phosphatase 3 (Lebrin et al., 1999; Perez and Avila, 1999; Castelli et al., 2004).  
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5.4 Inhibition of CK2 alters AMPA receptor localization 
 
GluR1 and GluR2 contain many residues that are consensus sites for phosphorylation by 
various protein kinases, and it has been shown that phosphorylation of these subunits is an 
important type of post-translational modification that regulates AMPA receptor function (Santos 
et al., 2009).  However, although CK2 is known to regulate NMDA glutamate channel function 
in the hippocampus, it has not been shown to regulate AMPA receptor function (Lieberman and 
Mody, 1999; Kimura and Matsuki, 2008).  So, while it has been shown that nucleoside 
transporters critically modulate glutamatergic synaptic transmission (Ackley et al., 2003), and 
that adenosine uptake inhibitors, such as DPY, cause a decrease in extracellular field potential 
recordings (Dunwiddie and Diao, 2000), the effects of CK2 inhibition on AMPA receptor 
trafficking have not yet been extensively explored.   
Here, we report that treatment of hippocampal tissues with DMAT, TBB and DRB caused 
29-35% reduction in the surface localization of the GluR1 AMPA receptor subunit and a 40-56% 
reduction in the surface localization of the GluR2 AMPA receptor subunit.  Thus, it is possible 
that CK2 inhibitors contribute to a reduction in the membrane localization of GluR1 and GluR2-
containing AMPA receptors by enhancing adenosine A1 receptor activation, via a reduction in 
ENT1 and ENT2 at the plasma membrane and accumulation of extracellular adenosine tone, as 
summarized in Figure 5.1.  Indeed, ischemic insults, which rise extracellular levels of adenosine, 
are thought to cause remodeling of AMPA receptor subunits and a long-lasting switch in AMPA 
receptor phenotype, from GluR2-containing to GluR2-lacking receptors (Liu and Zukin, 2007).  
Although the reduction in the Ca
2+
-permeable GluR1 subunit seen here was not anticipated, it is 
probable that there was a simultaneous reduction in GluR1 and GluR2 AMPA receptor subunits, 
as they often exist together as heteromeric AMPA receptors, which are known to follow the same 
sorting as GluR2 homomers (Lee et al., 2004).   
While we saw that there was a reduction in the amount of GluR1 and GluR2 protein 
expressed in the membrane fraction of hippocampal cell lysates, there was no apparent increase 
in the amount of GluR1 or GluR2 in the cytosol.  It is known that there are endogenous mRNAs 
encoding these AMPA receptor subunits that are localized in proximal and distal dendrites of 
hippocampal neurons (Grooms et al., 2006), suggesting that the composition and abundance of 
receptors is regulated by local synthesis (Santos et al., 2009).  Additionally, CK2 has many 
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substrates that are known transcription factors, which are also involved in the regulation of 
synaptic transmission (Blanquet, 2000).  So, while it is possible that CK2 inhibition caused a 
reduction in the transcription of these AMPA receptor subunits, based on the time course of the 
treatments in this study, it is unlikely that the changes membrane localization seen here are due to 
a transcriptional effect of CK2. 
Recent studies show that after high frequency stimulation there is a reversible increase in 
GluR1 and GluR2 protein levels in synaptosomes isolated from the hippocampal CA1 region (Lu 
et al., 2002; Santos et al., 2009).  Additionally, it has been shown that CK2 activity is associated 
with synaptosomes (Girault et al., 1990; Blanquet, 2000) and that CK2 activity is transiently 
increased after high frequency stimulation (Charriaut-Marlangue et al., 1991).  Thus, inhibition 
of CK2 may cause a reduction in the GluR1 and GluR2 AMPA receptor subunits at the synapse, 
similar to what was seen in the whole hippocampal membrane fraction.  However, densitometry 
analysis of GluR1 and GluR2 at the neuronal synapse revealed that there was no significant 
change in the localization of either GluR1 or GluR2 in this region of the cell after incubation 
with CK2 inhibitors (p>0.05) or the direct ENT inhibitor, DPY (p>0.05), which is expected to 
increase extracellular adenosine tone.  The adenosine analogue CPA also failed to cause a 
significant change (p>0.05) in the localization of GluR1 or GluR2 in synaptosomal fractions, 
which, based on previous work from our lab, would be expected to produce a reduction in the 
membrane localization of these proteins.  It is possible however, that the changes in GluR1 and 
GluR2 localization that are seen in the membrane fraction are occurring at extra-synaptic sites, 
and although AMPA receptors are considered neuronal receptors; they have been detected in 
glial cells (Santos et al., 2009), thus it is possible that astrocytic GluR1 and GluR2 may 
contribute to the observed changes in membrane-localized AMPA receptors subunits.  
It is already known that the level of CK2 activity is reduced after periods of brief 
ischemia (Hu and Wieloch, 1993), and although not presented in this thesis, our lab has shown 
that CK2 inhibition in the presence of hypoxia causes a significant reduction in the membrane 
localization of ENT1.  Furthermore, it was found that CK2 inhibition potentiates the 
internalization of GluR2 during hypoxia (Z. Chen, unpublished data).  These data suggest that a 
reduction in CK2 activity during hypoxia potentiates the changes in ENT1 and GluR2 
localization seen under normoxic conditions, and that this may contribute to enhanced neuronal 
injury during ischemic attacks.  Therefore, the regulation of CK2 activity may be an important 
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target for neuroprotective strategies.  Consistent with our observations, another study, of human 
umbilical vein endothelium exposed to a hypoxic environment, has shown a reduction in hENT1 
function but an increase in extracellular adenosine concentration (Casanello et al., 2005).  
However, chronic hypoxia has been suggested to cause a down-regulation of rENT1 (Kobayashi 
and Millhorn, 2001) and mENT1 mRNA which is dependent on the down-regulation of PKCε 
(Chaudary et al., 2004).  Thus, it is possible that regulatory mechanisms other than the inhibition 
of CK2-mediated phosphorylation of ENTs contribute to the hypoxia-induced reduction in ENT1 
localization seen here.  
It is well known that the extracellular level of adenosine is enhanced during both 
metabolic insults such as ischemia as well as with the inhibition of ENTs, and it is widely 
accepted that enhanced extracellular adenosine levels produce neuroprotective benefits (Cunha, 
2001; Dunwiddie and Masino, 2001; Olsson et al., 2004; Fredholm et al., 2005).  However, 
unlike the A1 receptor, activation of the A2a receptors may contribute to neuronal damage, as the 
antagonism of A2a receptors has been shown to offer neuroprotection in ischemic and 
excitotoxic models (Fredholm et al., 2005).  It is also known that adenosine stimulates the release 
of astrocytic glutamate via an A2a adenosine receptor/PKA pathway (Nishizaki, 2004).  Thus, it 
is possible that ENT inhibition may result in enhanced neuronal excitotoxicity via A2a receptors.  
In the hippocampus, A1 receptor density is reduced with age, whereas the A2a receptor density is 
increased (Cunha et al., 1995).  Additionally, A2a receptor-mediated facilitation of hippocampal 
synaptic transmission is enhanced with age, whereas A1 receptor signaling becomes less efficient 
(Lopes et al., 1999b; Cunha, 2001; Rebola et al., 2003).  This suggests that with age, when the 
risk of ischemic neuronal injury is increased, the A2a adenosine receptor-mediated pathway may 
become the dominant pathway for adenosine signaling. Therefore, increases in extracellular 
adenosine may cause some neuronal damage in an A2a receptor-dependent mechanism.   
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Figure 5.1.  Proposed model for the CK2-mediated regulation of ENT1, ENT2 and AMPAR subunits GluR1 
and GluR2 surface localization in the rat hippocampus. Potential coupling between ENTs and GluR subunits 
may be intimately linked with the adenosine A1 receptor (A1R) signaling.  Phosphorylation of ENTs by protein 
kinase CK2, promotes ENT surface localization. Treatment with CK2 inhibitors DMAT, TBB, or DRB leads to 
reduction in ENT surface localization, and subsequent rise in extracellular adenosine tone.  Extracellular adenosine 
acts on A1Rs, causing the activation of p38 MAPK and JNK, and in turn, a reduction in the surface localization of 
GluR1 and GluR2 AMPAR subunits. Our evidence also suggests a physical interaction between ENTs and GluR1 
and GluR2, thus these AMPA receptors may be internalized with ENTs in a protein complex. Treatment with ENT 
inhibitors DPY and NBTI leads to increased adenosine tone extracellularly, depending on the extent to which they 
block adenosine efflux/influx, and therefore may cause AMPAR subunit redistribution. The mechanism by which 
CK2-mediated phosphorylation regulates the membrane localization of ENT1 and ENT2 requires further 
investigation, as we could not determine whether or not CK2 inhibition had any affect on ENT transcription, or 
whether it was a post-translational effect.     
 
 
5.5 ENT and AMPA receptor localization is temperature sensitive 
 
It has been suggested that ENTs are sensitive to changes in temperature (Dunwiddie and 
Diao, 2000); therefore we wanted to determine if the membrane localization of ENT1 or ENT2 
was more or less sensitive to direct inhibition with varying temperatures.  Here, we report a 
significant increase in the localization of the 60 kDa ENT1 protein in the membrane fraction of 
hippocampal tissue slices that were incubated with the ENT1 inhibitor NBTI, at room 
temperature.  In addition to the changes observed in the 60 kDa protein band, the membrane 
localization of the 50 kDa ENT1 was significantly enhanced after treatment with NBTI (10nM), 
when compared to the control.  A change in the protein level of the 50 kDa band was not seen 
with incubation of CK2 inhibitors. 
In comparison to our findings, a study done by Torres et al. in 1992, on adrenal 
chromaffin cells, showed that NBTI binding caused quick internalization of the ENT1 transporter 
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protein (Torres et al., 1992).  While it is possible that the inconsistencies between our study and 
the one by Torres and colleagues may be due to differences in the temperature that the two 
studies were performed at, we did not observe any significant change in the localization of the 
ENT proteins at 35°C, which is a more physiological temperature and closer to that used by 
Torres et al.  However, the opposing effects of NBTI on ENT1 localization may also reflect 
differences in the two experimental models or the treatment incubation times.   
 In this set of experiments, neither concentration of NBTI caused any significant change 
in the membrane localization of ENT2 at room temperature.  This was expected since NBTI is a 
highly selective inhibitor of ENT1, and therefore, should not have an effect on the ENT2 
transporter at the concentrations used (Baldwin et al., 1999).  However, the non-selective ENT 
inhibitor, DPY had no significant effect of the localization of ENT2 in the membrane fraction of 
the cells treated at room temperature.  The extracellular adenosine tone is known to be 2-fold 
higher at room temperature than it is at 32°C, which is speculated to result from the reduced 
function of ENT2 at lower temperatures (Dunwiddie and Diao, 2000).  Thus, it is possible that a 
reduction in the membrane localization of ENT2 would not be detectible because its membrane 
localization is already quite low at this temperature.     
In the membrane fraction of the cell, inhibition with NBTI at room temperature did not 
cause a statistically significant (p>0.05) change in localization of GluR1 or GluR2.  Although a 
down-regulation of these subunits was anticipated, adenosine transport blockers can have varying 
effects on extracellular adenosine concentrations depending on the extent to which they block 
either efflux or uptake of adenosine (Phillis et al., 1989; Andine et al., 1990; Gu et al., 1995; 
Gidday et al., 1996). Therefore, the inhibition of adenosine transport may not have been 
sufficient to elevate the extracellular adenosine tone to the level needed for prolonged A1 
receptor activation and the subsequent reduction of GluR1/GluR2 membrane localization.   
There was no significant change in the localization of any of the proteins studied at 35°C 
and there were no significant changes in the localization of any of the proteins in the cytosolic 
fraction at room temperature or 35°C.  However, since there were no significant changes among 
the proteins studied at the higher temperature, these data suggest that enhanced protein 
degradation was likely a confounding factor, making it difficult to explain any CK2-mediated 
changes in ENTs localization at more physiological temperatures.  
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5.6 Future directions 
 
As discussed previously, the CK2-mediated phosphorylation of ENTs has the potential to 
modify synaptic transmission in such a way that makes hippocampal neurons more vulnerable to 
excitotoxicity.  The literature has yet to show substantial functional evidence to support this 
hypothesis.  Consequently, further experimentation is required to confirm that an increase in 
extracellular adenosine concentration after CK2 inhibition alters AMPA receptor-mediated 
synaptic transmission and neuronal health.  The work presented in this thesis suggests that ENT 
surface localization is influenced by CK2-mediated phosphorylation, that being said, it would be 
interesting to determine whether the surface localization of ENTs in ENT1 over-expressing mice 
(Parkinson et al., 2009) is more susceptible to manipulation of CK2.  Moreover, to prove the 
direct phosphorylation of ENTs by CK2, site directed mutagenesis of the serine moiety in ENT1 
and ENT2 and localization studies in a transient expression system in cell culture could be 
performed (Han et al., 1999).  
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CHAPTER 6 
 
CONCLUSION 
 
 
The results of this thesis provide novel evidence that inhibition of CK2 activity decreases 
the concentration of ENT1, ENT2 and GluR1 and GluR2-containing AMPA receptors in the 
plasma membrane fraction of rat hippocampal tissue.  Comparison of levels in membrane and 
cytosol suggest this may be due to changes in localization of these proteins mediated by CK2 
activity.  Together, these results suggest that CK2-mediated phosphorylation can influence the 
localization and function of ENTs and AMPA receptor subunits.  Unpublished data from our lab 
also showed that during hypoxia the CK2 inhibitors caused a more marked inhibition of surface 
localization of ENT1 and GluR2 subunits, implying that these changes would exacerbate 
ischemia-induced neuronal damage (personal communication, Z. Chen).  This is an important 
finding since memory loss is one of the most common symptoms following a stroke and can be 
caused, in part, by neuronal damage in the hippocampus.  Harnessing this pathway as a means to 
control extracellular levels of adenosine could provide neuroprotective targets during ischemic 
insult to the brain. 
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